STOCK TITAN

Callan JMB loss widens to $7.18M; going-concern warning

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

CALLAN JMB INC. reported third-quarter revenue of $1,146,699, down from $1,446,917 a year earlier; nine-month revenue was $3,629,167 versus $4,562,604. Nine-month net loss widened to $7,181,856 from $5,373,327, while nine-month operating cash use was $3,999,236. Cash and cash equivalents were $1,776,719 at September 30, 2026.

The company said substantial doubt about its ability to continue as a going concern within one year after the financial statements were issued was not alleviated. Its subsidiary’s $1,000,000 line of credit was fully drawn; maturity was extended from October 29, 2026 to January 27, 2027. In October 2026, CALLAN JMB completed an additional $4.0 million ELOC sale, with net proceeds of $3.66 million. The amended ELOC permits up to $75.0 million in common-stock sales, subject to a $1.00 closing-price floor for purchase notices and a 4.99% investor ownership cap.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

How the balance works

Positive

  • None.

Negative

  • Major pointGoing-concern doubt remains; cash was $1,776,719 at September 30, 2026.
  • Moderate pointNine-month revenue was $3,629,167, versus $4,562,604 a year earlier.
  • Moderate pointNine-month net loss widened to $7,181,856 from $5,373,327.

Filing Explained

The separate ATM had not been used as of September thirtieth, so it had generated neither shares nor cash.

Callan JMB reports that its $2,000,000 ELOC draw was partly settled by September 30, 2026: 906,000 shares had been delivered by then, and a further 288,744 were issued on October 8, 2026, completing 1,194,744 shares for that draw. The completed issuance increases the share count and reduces existing holders’ percentage ownership, absent offsetting changes.

Separately, the company could sell up to $5,000,000 through its ATM program, but by September 30, 2026 it had sold no shares through that program and received no proceeds from it.

Third-quarter revenue $1,146,699 Three months ended September 30, 2026; $1,446,917 in 2025
Nine-month revenue $3,629,167 Nine months ended September 30, 2026; $4,562,604 in 2025
Nine-month net loss $7,181,856 Nine months ended September 30, 2026; $5,373,327 in 2025
Operating cash used $3,999,236 Nine months ended September 30, 2026
Cash and cash equivalents $1,776,719 As of September 30, 2026
Line of credit $1,000,000 Fully drawn as of September 30, 2026
ELOC available amount Up to $75.0 million Aggregate common-stock sales permitted under the amended agreement
October ELOC net proceeds $3.66 million Net proceeds from an additional $4.0 million sale in October 2026
substantial doubt financial
"substantial doubt about the Company’s ability to continue as a going concern"
Equity Line of Credit (ELOC) financial
"Equity Line of Credit (ELOC) Facility"
An equity line of credit (ELOC) is a flexible financing agreement that lets a company draw cash over time by issuing new shares to a lender or investor up to a preset limit. It works like a credit line or charge card for cash needs, but payment comes in the form of additional stock rather than loan principal. Investors should care because it provides quick liquidity for the company but can dilute existing shareholders and affect share price and ownership over time.
derivative liability financial
"accounted for as a derivative liability measured at fair value"
A derivative liability is an obligation a company owes because of a derivatives contract—such as an option, future, swap, or forward—that has moved against it and now has negative value. Think of it like a settled bet that turned into a bill: if market moves go the other way, the company may have to pay cash or deliver assets. Investors care because these liabilities can create sudden losses, add leverage or counterparty risk, and change a company’s true financial exposure beyond its everyday operations.
cost-to-cost method financial
"measures progress toward completion using the cost-to-cost method"
anti-dilutive financial
"these shares were anti-dilutive and excluded from diluted net loss per share"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.
net realizable value financial
"Inventory is stated at the lower of cost or net realizable value"
Net realizable value is the estimated amount a company expects to receive from selling an asset—typically inventory or a receivable—after subtracting any costs needed to finish, sell, or collect it. For investors it shows whether assets on the balance sheet are likely to convert into cash at their stated value, much like estimating how much you’d actually get from a garage sale after cleaning and listing fees; large gaps can signal future write-downs or weaker earnings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the purchase limits and pricing rules for CJMB’s amended ELOC?

CJMB’s amended ELOC allows purchase notices of $500,000 to $2,000,000 each, within a $75.0 million aggregate amount. Regular purchases are priced at 95% and exempt purchases at 90% of the lowest daily trading price during the measurement period; pricing may be 75% and 80%, respectively, if trading is suspended or the shares are delisted. Purchase notices are barred below a $1.00 closing price.

What are the interest rate and maturity of CJMB’s line of credit?

At September 30, 2026, the weighted-average rate on the $1,000,000 line was 7.25%; contractual interest is the Wall Street Journal prime rate plus 0.50%, subject to a 6.00% floor. The maturity was extended from October 29, 2026 to January 27, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 --12-31 0002032545 http://fasb.org/us-gaap/2026#UsefulLifeTermOfLeaseMember 0002032545 2026-01-01 2026-09-30 0002032545 2026-11-13 0002032545 2026-09-30 0002032545 2025-12-31 0002032545 2026-07-01 2026-09-30 0002032545 2025-07-01 2025-09-30 0002032545 2025-01-01 2025-09-30 0002032545 us-gaap:PreferredStockMember 2025-12-31 0002032545 us-gaap:CommonStockMember 2025-12-31 0002032545 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0002032545 us-gaap:RetainedEarningsMember 2025-12-31 0002032545 us-gaap:PreferredStockMember 2026-03-31 0002032545 us-gaap:CommonStockMember 2026-03-31 0002032545 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0002032545 us-gaap:RetainedEarningsMember 2026-03-31 0002032545 2026-03-31 0002032545 us-gaap:PreferredStockMember 2026-06-30 0002032545 us-gaap:CommonStockMember 2026-06-30 0002032545 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0002032545 us-gaap:RetainedEarningsMember 2026-06-30 0002032545 2026-06-30 0002032545 us-gaap:PreferredStockMember 2024-12-31 0002032545 us-gaap:CommonStockMember 2024-12-31 0002032545 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0002032545 us-gaap:RetainedEarningsMember 2024-12-31 0002032545 2024-12-31 0002032545 us-gaap:PreferredStockMember 2025-03-31 0002032545 us-gaap:CommonStockMember 2025-03-31 0002032545 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0002032545 us-gaap:RetainedEarningsMember 2025-03-31 0002032545 2025-03-31 0002032545 us-gaap:PreferredStockMember 2025-06-30 0002032545 us-gaap:CommonStockMember 2025-06-30 0002032545 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0002032545 us-gaap:RetainedEarningsMember 2025-06-30 0002032545 2025-06-30 0002032545 us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0002032545 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0002032545 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0002032545 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0002032545 2026-01-01 2026-03-31 0002032545 us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0002032545 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0002032545 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0002032545 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0002032545 2026-04-01 2026-06-30 0002032545 us-gaap:PreferredStockMember 2026-07-01 2026-09-30 0002032545 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0002032545 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0002032545 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0002032545 us-gaap:PreferredStockMember 2025-01-01 2025-03-31 0002032545 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0002032545 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0002032545 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0002032545 2025-01-01 2025-03-31 0002032545 us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0002032545 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0002032545 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0002032545 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0002032545 2025-04-01 2025-06-30 0002032545 us-gaap:PreferredStockMember 2025-07-01 2025-09-30 0002032545 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0002032545 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0002032545 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0002032545 us-gaap:PreferredStockMember 2026-09-30 0002032545 us-gaap:CommonStockMember 2026-09-30 0002032545 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0002032545 us-gaap:RetainedEarningsMember 2026-09-30 0002032545 us-gaap:PreferredStockMember 2025-09-30 0002032545 us-gaap:CommonStockMember 2025-09-30 0002032545 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0002032545 us-gaap:RetainedEarningsMember 2025-09-30 0002032545 2025-09-30 0002032545 CJMB:CallanJMBServicesPrivateLimitedMember 2026-09-30 0002032545 2026-07-29 0002032545 2026-10-01 2026-10-31 0002032545 CJMB:StockWarrantsMember 2025-01-01 2025-03-31 0002032545 2025-01-01 2025-12-31 0002032545 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerOneMember 2026-07-01 2026-09-30 0002032545 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerOneMember 2025-07-01 2025-09-30 0002032545 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerOneMember 2026-01-01 2026-09-30 0002032545 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerOneMember 2025-01-01 2025-09-30 0002032545 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerTwoMember 2026-07-01 2026-09-30 0002032545 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerTwoMember 2025-07-01 2025-09-30 0002032545 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerTwoMember 2026-01-01 2026-09-30 0002032545 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerTwoMember 2025-01-01 2025-09-30 0002032545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerOneMember 2026-01-01 2026-09-30 0002032545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerOneMember 2025-01-01 2025-12-31 0002032545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerTwoMember 2026-01-01 2026-09-30 0002032545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerTwoMember 2025-01-01 2025-12-31 0002032545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerThreeMember 2026-01-01 2026-09-30 0002032545 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CJMB:CustomerThreeMember 2025-01-01 2025-12-31 0002032545 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember CJMB:VendorOneMember 2026-01-01 2026-09-30 0002032545 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember CJMB:VendorOneMember 2025-01-01 2025-12-31 0002032545 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember CJMB:VendorTwoMember 2026-01-01 2026-09-30 0002032545 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember CJMB:VendorTwoMember 2025-01-01 2025-12-31 0002032545 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember CJMB:VendorThreeMember 2026-01-01 2026-09-30 0002032545 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember CJMB:VendorThreeMember 2025-01-01 2025-12-31 0002032545 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember CJMB:VendorTwoMember 2026-07-01 2026-09-30 0002032545 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember CJMB:VendorTwoMember 2025-07-01 2025-09-30 0002032545 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember CJMB:VendorTwoMember 2026-01-01 2026-09-30 0002032545 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember CJMB:VendorTwoMember 2025-01-01 2025-09-30 0002032545 us-gaap:ComputerEquipmentMember srt:MinimumMember 2026-09-30 0002032545 us-gaap:ComputerEquipmentMember srt:MaximumMember 2026-09-30 0002032545 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2026-09-30 0002032545 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2026-09-30 0002032545 us-gaap:LeaseholdImprovementsMember 2026-09-30 0002032545 CJMB:EmergencyPreparednessMember 2026-07-01 2026-09-30 0002032545 CJMB:EmergencyPreparednessMember 2025-07-01 2025-09-30 0002032545 CJMB:EmergencyPreparednessMember 2026-01-01 2026-09-30 0002032545 CJMB:EmergencyPreparednessMember 2025-01-01 2025-09-30 0002032545 CJMB:SpecialtyPackagingMember 2026-07-01 2026-09-30 0002032545 CJMB:SpecialtyPackagingMember 2025-07-01 2025-09-30 0002032545 CJMB:SpecialtyPackagingMember 2026-01-01 2026-09-30 0002032545 CJMB:SpecialtyPackagingMember 2025-01-01 2025-09-30 0002032545 CJMB:GovernmentalMember 2026-07-01 2026-09-30 0002032545 CJMB:GovernmentalMember 2025-07-01 2025-09-30 0002032545 CJMB:GovernmentalMember 2026-01-01 2026-09-30 0002032545 CJMB:GovernmentalMember 2025-01-01 2025-09-30 0002032545 CJMB:NonGovernmentalMember 2026-07-01 2026-09-30 0002032545 CJMB:NonGovernmentalMember 2025-07-01 2025-09-30 0002032545 CJMB:NonGovernmentalMember 2026-01-01 2026-09-30 0002032545 CJMB:NonGovernmentalMember 2025-01-01 2025-09-30 0002032545 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0002032545 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0002032545 us-gaap:RestrictedStockMember 2026-01-01 2026-09-30 0002032545 us-gaap:RestrictedStockMember 2025-01-01 2025-09-30 0002032545 CJMB:StockWarrantsMember 2026-01-01 2026-09-30 0002032545 CJMB:StockWarrantsMember 2025-01-01 2025-09-30 0002032545 CJMB:ContingentlySharesIssuableMember 2026-01-01 2026-06-30 0002032545 CJMB:ContingentlySharesIssuableMember 2025-01-01 2025-09-30 0002032545 us-gaap:FairValueInputsLevel1Member 2026-09-30 0002032545 us-gaap:FairValueInputsLevel2Member 2026-09-30 0002032545 us-gaap:FairValueInputsLevel3Member 2026-09-30 0002032545 CJMB:ColdchainTechnologyServicesLLCMember 2026-07-29 0002032545 2026-07-29 2026-07-29 0002032545 CJMB:FirstUnitedBankAndTrustCoMember 2026-07-29 2026-07-29 0002032545 CJMB:ColdchainTechnologyServicesLLCMember 2026-07-01 2026-09-30 0002032545 us-gaap:ServiceMember CJMB:HealthHeroAmericaMember 2026-01-01 2026-09-30 0002032545 CJMB:HealthHeroAmericaMember 2026-09-30 0002032545 CJMB:HealthHeroAmericaMember 2025-12-31 0002032545 CJMB:ColdChainDeliverySystemsMember 2026-09-30 0002032545 CJMB:ColdChainDeliverySystemsMember 2025-12-31 0002032545 CJMB:OutlawRunRanchMember 2026-01-01 2026-09-30 0002032545 CJMB:OutlawRunRanchMember 2026-09-30 0002032545 CJMB:OutlawRunRanchMember 2025-12-31 0002032545 CJMB:WarehouseAssetManagementMember 2026-01-01 2026-09-30 0002032545 CJMB:WarehouseAssetManagementMember 2026-09-30 0002032545 CJMB:WarehouseAssetManagementMember 2025-12-31 0002032545 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0002032545 us-gaap:RelatedPartyMember 2026-07-01 2026-09-30 0002032545 us-gaap:RelatedPartyMember 2025-07-01 2025-09-30 0002032545 us-gaap:RelatedPartyMember 2026-01-01 2026-09-30 0002032545 us-gaap:RelatedPartyMember 2025-01-01 2025-09-30 0002032545 CJMB:MonarchPropertyManagementMember 2026-07-01 2026-09-30 0002032545 CJMB:MonarchPropertyManagementMember 2026-01-01 2026-09-30 0002032545 CJMB:MonarchPropertyManagementMember 2026-09-30 0002032545 CJMB:MonarchPropertyManagementMember 2025-12-31 0002032545 CJMB:ColdchainTechnologyServicesLLCMember 2026-07-29 0002032545 us-gaap:IPOMember 2025-02-01 2025-02-28 0002032545 us-gaap:IPOMember 2025-02-28 0002032545 us-gaap:OverAllotmentOptionMember 2025-02-01 2025-02-28 0002032545 us-gaap:OverAllotmentOptionMember 2025-02-28 0002032545 CJMB:UnderwritersMember 2025-02-28 0002032545 2025-02-01 2025-02-28 0002032545 2025-02-28 0002032545 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0002032545 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0002032545 us-gaap:RestrictedStockUnitsRSUMember CJMB:ThreeNonemployeeDirectorsMember 2026-01-01 2026-09-30 0002032545 us-gaap:RestrictedStockUnitsRSUMember 2026-07-01 2026-09-30 0002032545 us-gaap:StockOptionMember 2026-07-30 2026-07-30 0002032545 us-gaap:CommonStockMember CJMB:EquityLineOfCreditMember 2026-01-01 2026-09-30 0002032545 us-gaap:CommonStockMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0002032545 CJMB:ThreeNonemployeeDirectorsMember 2026-01-01 0002032545 us-gaap:PerformanceSharesMember 2026-01-01 2026-09-30 0002032545 CJMB:MarketBasedAwardMember 2026-01-01 2026-09-30 0002032545 CJMB:StockWarrantsMember 2025-02-01 2025-02-28 0002032545 CJMB:StockWarrantsMember 2025-02-28 0002032545 CJMB:ELOCPurchaseAgreementMember 2025-07-24 2025-07-24 0002032545 CJMB:ELOCPurchaseAgreementMember 2025-07-24 0002032545 srt:MinimumMember 2025-07-24 0002032545 srt:MaximumMember 2025-07-24 0002032545 2025-07-24 0002032545 us-gaap:CommonStockMember CJMB:EquityLineOfCreditMember 2026-01-01 2026-01-31 0002032545 CJMB:EquityLineOfCreditMember 2026-03-10 0002032545 CJMB:RestatedPurchaseAgreementMember srt:MinimumMember 2026-08-18 2026-08-18 0002032545 CJMB:RestatedPurchaseAgreementMember srt:MaximumMember 2026-08-18 2026-08-18 0002032545 CJMB:RestatedPurchaseAgreementMember 2026-08-18 2026-08-18 0002032545 2026-08-18 0002032545 CJMB:RestatedPurchaseAgreementMember 2025-01-01 2025-12-31 0002032545 2025-08-20 0002032545 2026-08-20 2026-08-20 0002032545 2026-08-27 2026-08-27 0002032545 2026-09-14 2026-09-14 0002032545 us-gaap:CommonStockMember CJMB:HexstoneCapitalLLCMember us-gaap:SubsequentEventMember 2026-10-01 2026-10-01 0002032545 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-10-01 2026-10-01 0002032545 us-gaap:InvestorMember 2025-07-24 2025-07-24 0002032545 2025-07-24 2025-07-24 0002032545 us-gaap:CommonStockMember 2026-08-18 2026-08-18 0002032545 CJMB:EquityLineOfCreditMember 2025-08-24 2025-08-24 0002032545 CJMB:ATMOfferingProgramMember 2025-05-26 2025-05-26 0002032545 CJMB:ATMOfferingProgramMember 2026-01-01 2026-09-30 0002032545 CJMB:MonteCarloSimulationModelMember 2025-07-24 2025-07-24 0002032545 CJMB:MonteCarloSimulationModelMember 2026-01-01 2026-09-30 0002032545 CJMB:MonteCarloSimulationModelMember 2025-07-24 0002032545 CJMB:MonteCarloSimulationModelMember 2026-09-30 0002032545 CJMB:ProfessionalServiceAgreementMember 2026-01-01 2026-09-30 0002032545 CJMB:ExecutiveEmployeeMember CJMB:EmploymentAgreementMember 2026-01-01 2026-09-30 0002032545 CJMB:ExecutiveEmployeeMember CJMB:EmploymentAgreementMember 2026-09-30 0002032545 CJMB:ExecutiveEmployeeMember 2026-09-30 0002032545 us-gaap:SellingGeneralAndAdministrativeExpense us-gaap:EmployeeStockOptionMember 2026-07-01 2026-09-30 0002032545 us-gaap:SellingGeneralAndAdministrativeExpense us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0002032545 us-gaap:SellingGeneralAndAdministrativeExpense us-gaap:EmployeeStockOptionMember 2026-01-01 2026-09-30 0002032545 us-gaap:SellingGeneralAndAdministrativeExpense us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0002032545 us-gaap:PerformanceSharesMember srt:ChiefExecutiveOfficerMember 2025-01-01 2025-09-30 0002032545 CJMB:MarketBasedAwardMember srt:ChiefExecutiveOfficerMember 2025-01-01 2025-09-30 0002032545 CJMB:MarketBasedAwardMember srt:ChiefExecutiveOfficerMember 2026-07-01 2026-09-30 0002032545 CJMB:MarketBasedAwardMember srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0002032545 us-gaap:SellingGeneralAndAdministrativeExpense us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0002032545 us-gaap:RestrictedStockUnitsRSUMember 2026-09-30 0002032545 us-gaap:MonteCarloModelMember 2026-01-01 2026-09-30 0002032545 srt:MinimumMember us-gaap:MonteCarloModelMember 2026-01-01 2026-09-30 0002032545 srt:MaximumMember us-gaap:MonteCarloModelMember 2026-01-01 2026-09-30 0002032545 us-gaap:PerformanceSharesMember 2025-12-31 0002032545 us-gaap:RestrictedStockMember 2025-12-31 0002032545 us-gaap:PerformanceSharesMember 2026-01-01 2026-03-31 0002032545 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0002032545 us-gaap:PerformanceSharesMember 2026-03-31 0002032545 us-gaap:RestrictedStockMember 2026-03-31 0002032545 us-gaap:PerformanceSharesMember 2026-04-01 2026-06-30 0002032545 us-gaap:RestrictedStockMember 2026-04-01 2026-06-30 0002032545 us-gaap:PerformanceSharesMember 2026-06-30 0002032545 us-gaap:RestrictedStockMember 2026-06-30 0002032545 us-gaap:PerformanceSharesMember 2026-07-01 2026-09-30 0002032545 us-gaap:RestrictedStockMember 2026-07-01 2026-09-30 0002032545 us-gaap:PerformanceSharesMember 2026-09-30 0002032545 us-gaap:RestrictedStockMember 2026-09-30 0002032545 CJMB:StockWarrantsMember 2026-09-30 0002032545 CJMB:StockWarrantsMember 2025-02-25 2025-02-25 0002032545 srt:MinimumMember 2026-09-30 0002032545 srt:MaximumMember 2026-09-30 0002032545 2024-10-21 2024-10-21 0002032545 2024-10-21 0002032545 CJMB:LeaseAgreementMember 2025-01-01 2025-12-31 0002032545 CJMB:LeaseAgreementMember 2025-01-01 2025-01-01 0002032545 CJMB:LeaseAgreementMember 2024-12-31 2024-12-31 0002032545 CJMB:LongTermLeaseAgreementMember 2025-03-20 2025-03-20 0002032545 CJMB:LongTermLeaseAgreementMember 2025-03-19 2025-03-19 0002032545 CJMB:LongTermLeaseAgreementMember 2025-01-01 2025-12-31 0002032545 CJMB:RenewalLeaseAgreementMember 2026-02-24 2026-02-24 0002032545 CJMB:RenewalLeaseAgreementMember 2026-02-24 0002032545 us-gaap:SubsequentEventMember 2026-10-01 2026-10-31 0002032545 us-gaap:CommonStockMember us-gaap:SubsequentEventMember us-gaap:LineOfCreditMember 2026-10-01 2026-10-31 0002032545 us-gaap:CommonStockMember us-gaap:SubsequentEventMember us-gaap:LineOfCreditMember 2026-10-31 0002032545 us-gaap:CommonStockMember us-gaap:SubsequentEventMember CJMB:LineOfCreditOneMember 2026-10-01 2026-10-31 0002032545 us-gaap:CommonStockMember us-gaap:SubsequentEventMember CJMB:LineOfCreditOneMember 2026-10-31 0002032545 us-gaap:CommonStockMember us-gaap:SubsequentEventMember CJMB:LineOfCreditTwoMember 2026-10-01 2026-10-31 0002032545 us-gaap:CommonStockMember us-gaap:SubsequentEventMember CJMB:LineOfCreditTwoMember 2026-10-31 0002032545 us-gaap:CommonStockMember us-gaap:SubsequentEventMember CJMB:LineOfCreditThreeMember 2026-10-01 2026-10-31 0002032545 us-gaap:CommonStockMember us-gaap:SubsequentEventMember CJMB:LineOfCreditThreeMember 2026-10-31 0002032545 us-gaap:CommonStockMember us-gaap:SubsequentEventMember CJMB:LineOfCreditFourMember 2026-10-01 2026-10-31 0002032545 us-gaap:CommonStockMember us-gaap:SubsequentEventMember CJMB:LineOfCreditFourMember 2026-10-31 0002032545 us-gaap:SubsequentEventMember 2026-10-12 2026-10-12 0002032545 us-gaap:SubsequentEventMember us-gaap:LineOfCreditMember 2026-10-15 2026-10-15 0002032545 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember CJMB:SecuritiesPurchaseAgreementMember 2026-11-10 2026-11-10 0002032545 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember CJMB:SecuritiesPurchaseAgreementMember 2026-11-10 0002032545 srt:ScenarioPreviouslyReportedMember 2026-01-01 2026-06-30 0002032545 srt:RestatementAdjustmentMember 2026-01-01 2026-06-30 0002032545 2026-01-01 2026-06-30 0002032545 srt:ScenarioPreviouslyReportedMember 2026-06-30 0002032545 srt:RestatementAdjustmentMember 2026-06-30 0002032545 CJMB:RevisedMember 2026-06-30 0002032545 srt:ScenarioPreviouslyReportedMember 2026-04-01 2026-06-30 0002032545 srt:RestatementAdjustmentMember 2026-04-01 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CJMB:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to ____________

 

Commission file number: 001-42506

 

CALLAN JMB INC.

(Exact name of registrant as specified in its charter)

 

Nevada   99-0931141
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

244 Flightline Drive

Spring Branch, Texas 78070-6241

(Address of principal executive offices, including zip code)

 

Tel: (830) 438-0395

(Registrant’s telephone number, including area code)

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   CJMB   The Nasdaq Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☐ NO ☒

 

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES ☐ NO ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and emerging growth company in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if this registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☒

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 13, 2026, the Company had 10,662,319 shares of common stock, $0.001 par value, issued and outstanding.

 

Documents Incorporated by Reference: None.

 

 

 

 
 

 

CALLAN JMB INC.

FORM 10-Q

TABLE OF CONTENTS

 

PART I  
Item 1. Unaudited Financial Statements  
  Condensed Consolidated Balance Sheets as of September 30, 2026 (unaudited) and December 31, 2025 3
  Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 (unaudited) 4
  Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2026 and 2025 (unaudited) 5
  Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 (unaudited) 6
  Notes to Condensed Consolidated Financial Statements 7
Item 2. MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL AND RESULTS OF OPERATIONS 30
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 34
Item 4. CONTROLS AND PROCEDURES 34
PART II  
Item 1. LEGAL PROCEEDINGS 35
Item 1A. RISK FACTORS 35
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 35
Item 6 EXHIBITS 36
SIGNATURES 37

 

2

 

 

CALLAN JMB INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   September 30,
2026
(Unaudited)
   December 31,
2025
 
Assets        
Current Assets:          
Cash and cash equivalents  $1,776,719   $2,130,758 
Accounts receivable, net of allowance for credit losses of $112,692 and $61,675, respectively   755,038    343,246 
Inventory   198,287    243,285 
Other current assets   352,577    341,311 
Deferred offering costs   75,000    - 
Total current assets   3,157,621    3,058,600 
Right of use assets - operating lease   1,717,301    1,917,563 
Advances to affiliates   59,491    - 
Property and equipment, net of accumulated depreciation of $870,423 and $760,655, respectively   725,082    799,538 
Total assets  $5,659,495   $5,775,701 
           
Liabilities and Stockholders’ Equity          
Current Liabilities:          
Accounts payable  $538,212   $564,014 
Accrued expenses   810,333    502,183 
Corporate taxes payable   3,006    23,085 
Right of use liabilities –  operating lease   362,205    323,935 
Line of Credit   1,000,000    - 
Derivative liability   

754,000

    - 
Total current liabilities   3,467,756    1,413,217 
Right of use liabilities –  operating lease   1,696,980    1,663,229 
Deferred Tax liability   55,598    - 
Derivative liability   -    371,216 
Total long-term liabilities   1,752,578    2,034,445 
Total liabilities   5,220,334    3,447,662 
Commitments and Contingencies – Note 9   -    - 
Stockholders’ Equity          
Preferred stock - authorized 10,000,000 shares, $0.001 par value; zero issued and outstanding as of September 30, 2026 and December 31, 2025  $-   $- 
Common stock - authorized 190,000,000 shares, par value $0.001; 6,674,718 and 4,858,663 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   6,674    4,860 
Additional Paid in Capital   17,874,357    12,583,193 
Accumulated Deficit   (17,441,870)   (10,260,014)
Total Stockholders’ Equity   439,161    2,328,039 
Total Liabilities and Stockholders’ Equity  $5,659,495   $5,775,701 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

CALLAN JMB INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

                 
   Three months ended   Nine months ended 
   September 30, 2026   September 30, 2025   September 30, 2026   September 30, 2025 
Revenue  $1,146,699   $1,446,917   $3,629,167   $4,562,604 
Cost of revenue   677,531    953,610    2,065,570    2,812,334 
Gross profit   469,168    493,307    1,563,597    1,750,270 
Operating expenses                    
Selling, general and administrative expenses   2,669,722    2,372,465    6,902,736    6,274,343 
Operating loss   (2,200,554)   (1,879,158)   (5,339,139)   (4,524,073)
                     
Other income (expenses)                    
Interest income   8,127    1,372    11,156    5,621 
Interest expense   (12,923)   (473)   (15,344)   (536)
ELOC facility transaction expenses   (276,440)   (229,041)   (1,453,663)   (229,041)
Changes in fair value of derivative liability   (165,396)   (624,041)   (382,784)   (624,041)
Total other income (expenses)   (446,632)   (852,183)   (1,840,635)   (847,997)
Loss before income taxes   (2,647,186)   (2,731,341)   (7,179,774)   (5,372,070)
Provision (benefit) for income taxes   (3,058)   -    2,082    1,257 
Net Loss  $(2,644,128)  $(2,731,341)  $(7,181,856)  $(5,373,327)
Weighted average common shares outstanding - basic and diluted (See Note 2)   6,020,709    4,490,093    5,714,035    4,276,826 
Net loss per common share - basic and diluted (See Note 2)  $(0.44)  $(0.61)  $(1.26)  $(1.26)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

CALLAN JMB INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
   Preferred Stock   Common Stock   Additional
Paid in
   Accumulated   Total
Stockholders’
 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
January 1, 2026   -    -    4,858,663   $4,860   $12,583,193   $(10,260,014)  $2,328,039 
Net Loss   -    -    -    -    -    (3,215,054)   (3,215,054)
Issuance of ELOC Shares             768,705    768    2,091,454    -    2,092,222 
Stock based compensation   -    -    -    -    394,326    -    394,326 
Restricted stock unit awards vesting             18,750    18    (18)   -    - 
March 31, 2026   -   $-    5,646,118   $5,646   $15,068,955   $(13,475,068)  $1,599,533 
Net Loss   -    -    -    -    -    (1,231,923)   (1,231,923)
Stock based compensation   -    -    -    -    314,253    -    314,253 
Restricted stock unit awards vesting             18,750    19    (19)   -    - 
June 30, 2026 as previously reported   -   $-    5,664,868   $5,665   $15,383,189   $(14,706,991)  $681,863 
Immaterial revisions (See Note 11)             -   $-   $-   $(90,751)  $(90,751)
June 30, 2026 as revised   

-

   $

-

    

5,664,868

   $

5,665

   $

15,383,189

   $

(14,797,742

)  $

591,112

 
Net Loss   -    -    -    -    -    (2,644,128)   (2,644,128)
Stock based compensation   -    -    -    -    271,238    -    271,238 
Restricted stock unit awards vesting             16,350    16    (16)   -    - 
Issuance of ELOC Shares   -    -    906,000    906    2,090,534    -    2,091,440 
Common stocks issued for professional services   -    -    87,500    87    129,412    -    129,499 
September 30, 2026   -   $-    6,674,718   $6,674   $17,874,357   $(17,441,870)  $439,161 

 

   Preferred Stock   Common Stock   Additional
Paid in
   Accumulated   Total
Stockholders’
 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
January 1, 2025   -   $-    3,000,000   $3,000   $5,464,006   $(2,293,648)  $3,173,358 
Net Loss   -    -    -    -    -    (1,240,590)   (1,240,590)
Common stock issued in initial public offering, net of costs   -    -    1,280,000    1,280    3,950,588    -    3,951,868 
Common stock issued in initial public offering (over allotment), net of costs Stock based compensation   -    -    163,569    164    591,956    -    592,120 
Stock based compensation   -    -    -    -    330,825    -    330,825 
March 31, 2025   -   $-    4,443,569   $4,444   $10,337,375   $(3,534,238)  $6,807,581 
Net Loss   -    -    -    -    -    (1,401,396)   (1,401,396)
Stock based compensation   -    -    -    -    419,102    -    419,102 
Restricted stock unit awards vesting   -    -    37,500    38    (38)   -    - 
June 30, 2025   -   $-    4,481,069   $4,482   $10,756,439   $(4,935,634)  $5,825,287 
Net Loss             -    -   $-    (2,731,341)   (2,731,341)
Stock based compensation   -    -    -    -    404,915    -    404,915 
Restricted stock unit awards vesting   -         18,750    18    (18)   -    - 
Issuance of shares under the ELOC Facility (see Note 7)   -    -    123,208    123    598,668    -    598,791 
Commitment shares under ELOC Facility (see Note 7)   -    -    -    -    78,000    -    78,000 
September 30, 2025   -   $-    4,623,027   $4,623   $11,838,004   $(7,666,975)  $4,175,652 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

CALLAN JMB INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

         
   For the Nine months ended 
   September 30,
2026
   September 30,
2025
 
Cash flows from operating activities:          
Net Loss  $(7,181,856)  $(5,373,327)
Adjustment to reconcile net loss to net cash used in operating activities:          
Changes in fair value of derivative liability   382,784    624,041 
Depreciation and amortization   109,768    119,656 
Amortization of right-of-use assets   

238,999

    

226,099

 
Provision for credit losses   51,017    73,065 
Other non-cash expenses relating to ELOC Facility   1,368,662    179,041 
Common stocks issued for professional services   129,499    - 
Stock based compensation   979,817    1,154,842 
Changes in operating assets and liabilities:          
Accounts receivable   (462,809)   (395,995)
Inventory   44,998    (64,883)
Tax refund receivable   -    6,377 
Other current assets   (11,266)   (50,701)
Operating lease liabilities   33,284    (249,725)
Accounts payable and accrued expenses   282,348    (43,029)
Deferred revenue   -    (94,097)
Deferred tax liability   55,598    (6,602)
Corporate taxes payable   (20,079)   7,501 
Net cash used in operating activities  $(3,999,236)  $(3,887,737)
           
Cash flows used in investing activity          
Purchase of property and equipment   (35,312)   (616,896)
Net cash used in investing activity  $(35,312)  $(616,896)
           
Cash flows from (used in) financing activities:          
Related party loans   -    18,669 
Deferred offering costs   (75,000)    
Advances to affiliate   (59,491)   - 
Proceeds from IPO and overallotment, net   -    4,680,013 
Proceeds from line of credit   1,000,000    - 
Proceeds from offering of ELOC Facility   2,815,000    - 
Proceeds from issuance of shares under the ELOC Facility   -    497,750 
Net cash from financing activities  $3,680,509   $5,196,432 
Increase (decrease) in cash and cash equivalents   (354,039)   691,799 
Cash and cash equivalents at beginning of period   2,130,758    2,097,945 
Cash and cash equivalents at end of period  $1,776,719   $2,789,744 

 

   For the Nine months ended 
   September 30,
2026
   September 30,
2025
 
Supplemental disclosures of cash flow information:        
Cash paid for interest  $10,482   $536 
Lease incentives reimbursement  $280,115      
Supplemental disclosures of Non-Cash Financing and Investing Activities:          
Initial recognition of derivative liability  $-   $974,309 
Right of use assets acquired and operating lease liabilities recognized for new lease arrangement  $38,737   $708,321 
Right of use assets and operating lease liabilities due to lease modifications  $-   $704,927 
Fair value of Stock Warrants issued at IPO  $-   $144,358 
Deferred offering costs charged to additional paid-in-capital  $-   $136,025 
Restricted stock unit awards vesting (par value)  $53   $56 
Other non-cash expenses relating to ELOC Facility  $-   $48,791 
Issuance of common stock for ELOC-related consideration and expenses  $1,368,662   $- 
Commitment shares under ELOC Facility  $-   $78,000 
Common stocks issued for professional services  $129,499   $- 
Income taxes paid  $22,163   $- 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

6

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

NOTE 1 – NATURE OF OPERATIONS

 

Callan JMB Inc. (which may be referred to as “Callan,” “Callan JMB,” “CJMB”, “Company,” “we,” “us,” or “our”) was formed on January 24, 2024, in the state of Nevada for the purposes of reorganizing and becoming a holding company for Coldchain Technology Services, LLC and Callan JMB Services (India) Private Limited. CTS was formed on December 27, 2006, in the state of Texas and is our main operating subsidiary engaged in a vertically integrated logistics and fulfillment ecosystem that utilizes advanced predictive technology for the supply chain by guaranteeing the safety, effectiveness, and potency of every product handled to ensure product integrity, and to provide immediate response in time sensitive industries while ensuring environmental responsibility. Callan JMB Services (India) Private Limited is domiciled in Pune, Maharashtra, India and is 99.9% owned by Callan JMB and has minimal operations as of September 30, 2026. The Company’s headquarters are located in Spring Branch, Texas. Callan Power LLC was formed in August 2026 as part of Callan JMB’s diversification into critical infrastructure manufacturing. It is positioned as both a domestic manufacturing hub for critical electrical equipment and a strategic energy development platform through its oil and gas assets. As of September 30, 2026, Callan Power LLC has had no significant operations since its formation.

 

The interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2025 and notes thereto contained in the Company’s Form 10-K filed with the Securities and Exchange Commission.

 

Going Concern

 

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and other commitments in the normal course of business. As such, the financial statements do not include adjustments for the recoverability and classification of assets and their carrying amounts, or for the amount and classification of liabilities that may result should the Company be unable to continue as a going concern.

 

As of September 30, 2026, the Company had an accumulated deficit of $(17,441,870) and negative cash flow from operating activities of $(3,999,236) for the nine months ended September 30, 2026. In addition, the Company incurred a net loss of $(7,181,856) for the nine months ended September 30, 2026 and had cash and cash equivalents of $1,776,719 as of September 30, 2026. The Company has recurring losses, has not yet generated sufficient cash flows from operations to fund its activities, and expects to continue incurring operating losses and using cash in support of its business plan.

 

On July 29, 2026, the Company’s subsidiary, Coldchain Technology Services, LLC (“CTS”), entered into a $1,000,000 non-revolving line of credit with First United Bank and Trust Co to fund working capital, and the full amount was drawn during the quarter (see Note 4). The line is secured by substantially all of CTS’s assets and by assets pledged by, and guarantees from, related parties, and it restricts CTS from incurring additional debt or making distributions without the lender’s consent. As of September 30, 2026 the line is fully drawn and there is no further borrowing availability. The Line of Credit matures on October 29, 2026. As of the date these financial statements were issued, the Company has not made repayment and extended the terms by 90 days to Jan 27, 2027 (see Note 10).

 

7

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1 – NATURE OF OPERATIONS (CONTINUED)

 

Management considered the above circumstances and current maturity of line of credit, together with the Company’s cash on hand at September 30, 2026 stated above and its projected operating cash flows, in evaluating the Company’s ability to meet its obligations as they become due within one year after the date these financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. As a result of the conditions identified and the uncertainty regarding the achievability of management’s plans, substantial doubt about the Company’s ability to continue as a going concern has not been alleviated.

 

Since inception, the Company has funded its operations through operating cash flows, the ELOC Facility, and capital contributions or other funding from the Company’s CEO and largest shareholder. Management will continue to evaluate additional sources of capital, including equity and debt financing and support from the Company’s Chief Executive Officer and largest shareholder. In October 2026, the Company completed an additional $4.0 million sale under the ELOC, resulting in net proceeds of $3.66 million after transaction fees (see Note 10). However, the availability and terms of future financing are subject to market conditions, investor demand, and the Company’s operating performance, and there can be no assurance that additional capital will be available when needed or on acceptable terms.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation and Basis of Presentation

 

The Condensed Consolidated Financial Statements include all of the accounts of the Company and our subsidiaries. We have eliminated all significant intercompany transactions and balances in consolidation. In management’s opinion, all adjustments, consisting only of normal recurring accruals, necessary for a fair statement of our Condensed Consolidated Balance Sheet as of September 30, 2026, and our Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 have been made. The results set forth in our Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and in our Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the full year. The Condensed Consolidated Balance Sheet as of December 31, 2025 was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States (“GAAP”).

 

Reclassifications

 

Certain prior year amounts in the Consolidated Financial Statements and the notes thereto have been reclassified where necessary to conform to the current period’s presentation. These reclassifications did not affect the prior period’s total assets, total liabilities, stockholders’ equity, net income, or net cash used in operating and investing or net cash from financing activities.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions about future events that affect the amounts reported in the consolidated financial statements and the accompanying notes. Management bases its estimates on historical experience and other assumptions that it believes to be reasonable at the time. Actual results could differ from those estimates and any such differences may be material to the financial statements. Significant estimates are contained in the accompanying financial statements for the useful lives for depreciation and amortization of long-lived assets, allowance for credit losses, fair value of derivative liability, stock based compensation and the incremental borrowing rate used in determining the right-of-use assets and operating lease liabilities.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash with high credit quality financial institutions. The Company’s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. All cash amounts in excess of $250,000 are unsecured. The Company has a deposit placement agreement for Insured Cash Sweep Service (“ICS”). This service is a secured, and convenient way to access FDIC protection on large deposits, earn a return, and enjoy flexibility. The Company believes that the ICS agreement will mitigate its credit risk as it relates to uninsured FDIC amounts in excess of $250,000. At September 30, 2026 and December 31, 2025, the Company’s balances exceeded federally insured limits by approximately $1,002,437 and $1,701,861, respectively.

 

8

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Accounts Receivable

 

Accounts receivable are recorded at the invoiced amount, which is the amount the Company expects to collect from its customers. Generally, payment is due from customers within 30-90 days of the invoice date. On a regular basis, the Company evaluates its accounts receivable and establishes the allowance for credit losses based on an evaluation of certain criteria and evidence of collection uncertainty including historical collection trends, reasonable expectations of future collections, current economic trends and changes in customer payment patterns. Past-due receivable balances are written off when the Company’s collection efforts have been deemed unsuccessful. The Company maintains an allowance for credit losses to reserve for potential uncollectible receivables. The allowance for credit losses as of September 30, 2026 and December 31, 2025 are as follows:

  

   September 30,
2026
   December 31,
2025
 
Beginning balance  $61,675   $64,000 
Provision for credit losses   51,017    230,190 
Related allowances for written off accounts receivable   -    (152,568)
Reversal of allowance related to reinstated invoices previously charged off   -    (82,000)
Others   -    2,053 
Ending balance  $112,692   $61,675 

 

Credit Concentration

 

The concentration of credit risks in accounts receivable is due to certain large customers comprising the Company’s customer base throughout North America. The Company maintains policies over credit extension that include credit evaluations, credit limits and collection monitoring procedures on a customer-by-customer basis. However, the Company generally does not require collateral before services are performed.

 

The Company has two customers for the three and nine months ended September 30, 2026 and 2025 that make up in excess of 10% of revenue as follows:

 

                 
   Three Months Ended   Nine months ended 
Customer  September 30,
2026
   September 30,
2025
   September 30,
2026
   September 30,
2025
 
1   77%   49%   68%   55%
2   13%   17%   13%   10%

 

9

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

The Company has several customers as of September 30, 2026 and December 31, 2025 that make up in excess of 10% of accounts receivable as follows:

 

Customer  2026   2025 
1    79%   13%
2    12%   48%
3    5%   11%

 

The Company has three vendors as of September 30, 2026 and December 31, 2025 that make up in excess of 10% of accounts payable as follows:

 

Vendor  2026   2025 
1    35%   0%
2    13%   17%
3    12%   29%

 

The Company has one vendor for the nine months ended September 30, 2026 and 2025 that make up equal to or more than 10% of services rendered to us as follows:

 

                 
   Three Months Ended   Nine Months Ended 
Vendor  September 30, 2026   September 30, 2025   September 30, 2026   September 30, 2025 
1    8%   14%   11%   11%

 

Inventory

 

Inventory is stated at the lower of cost (using the first-in, first-out method (“FIFO”)) or net realizable value. We continually analyze our slow moving and excess inventories. Based on historical and projected sales volumes and anticipated selling prices, we determined that establishing a reserve was not necessary at this time. Inventory that is in excess of current and projected use is reduced by an allowance to a level that approximates its estimate of future demand. Products that are determined to be obsolete are written down to net realizable value. The Company’s inventory is comprised of raw materials for customer packaging needs as follows:

  

   (Unaudited)     
  

September 30,

2026

  

December 31,

2025

 
Raw materials  $198,287   $243,285 

 

Property and Equipment

 

Property and equipment, net, is stated at cost less accumulated depreciation. Expenditures for major renewals and improvements that extend the life or usefulness of the asset are capitalized. Items of an ordinary repair or maintenance nature are charged directly to operating expense as incurred. During the construction and development period of an asset, the costs incurred, including interest expense, are classified as construction-in-progress. When the asset is ready for its intended use, the asset is reclassified to an appropriate asset classification and depreciation, or amortization commences.

 

10

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Property and Equipment (Continued)

 

The Company depreciates and amortizes the capitalized cost of these assets, using the straight-line method, as follows:

   

Asset Classification:

Computer equipment 3-5 years

Furniture and fixtures 5-8 years

Leasehold improvements limited to lease term

 

The Company recognized depreciation expense of $35,543 and $43,256 for the three months ended September 30, 2026 and 2025, respectively, as well as $109,768 and $119,656 for the nine months ended September 30, 2026 and 2025 in its condensed consolidated statements of operations, respectively. Fully depreciated assets are retained in property and equipment and accumulated depreciation until they are removed from service.

 

The Company tests for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. An impairment in the carrying value of long-lived assets is recognized if the expected future undiscounted cash flows derived from the assets, or group of assets, are less than their carrying value. The Company did not record any impairment charges related to long-lived assets in the periods presented.

 

Revenue Recognition

 

The Company recognizes revenue when control of the promised goods or services is transferred to the Company’s customers. Revenue is recorded at the transaction price, which is the amount that reflects the consideration the Company expects to receive in exchange for providing the goods or services. The Company’s primary performance obligations in our contracts with customers are to provide services related to emergency preparedness or to deliver specialty packaging. Most of the Company’s revenues are for services, which are recognized over time as the related time and materials are incurred at contractually agreed-upon rates. Product revenues are recognized at a point in time when the products are either shipped or delivered and control transfers to the customer. The Company’s payment terms vary by the type of customer and the products or services offered. The periods between invoicing and when payments are due are not significant. Amounts billed to customers related to shipping and handling are classified as revenue and the Company’s shipping and handling costs are included in costs of revenues.

 

Services Contracts

 

The Company provides services contract for a customer. For this contract, the Company’s performance creates an asset for the customer with no alternative use to the Company, and the Company has an enforceable right to payment for performance completed to date. Accordingly, the Company recognizes revenue over time as the performance obligation is satisfied. The Company measures progress toward completion using the cost-to-cost method, an input method. Under this method, revenue is recognized in proportion to costs incurred to date relative to total estimated costs at completion. The Company believes this method best depicts the transfer of control to the customer because costs incurred are directly proportional to the Company’s progress in satisfying the performance obligation. Contract costs include direct materials, direct labor, subcontractor costs, and other costs directly related to contract performance.

 

Recognizing revenue under the cost-to-cost method requires estimates of total contract costs, expected margin, and progress to date. Changes in estimates, including contract modifications, are recognized on a cumulative catch-up basis in the period in which the change becomes known. If estimated costs at completion exceed the transaction price, the full anticipated loss is recognized in the period it becomes evident.

 

Amounts billed or collected in excess of revenue recognized are recorded as contract liabilities within deferred revenue. Revenue recognized in excess of amounts billed is recorded as a contract asset.

 

Disaggregation of Revenue

 

The following table presents our disaggregated revenues by distribution channel:

  

Sales by distribution channel:  2026   2025   2026   2025 
   Three Months Ended September 30,   Nine Months Ended September 30, 
Sales by distribution channel:  2026   2025   2026   2025 
Emergency preparedness  $962,685   $973,921   $2,889,766   $3,046,631 
Specialty packaging   184,014    472,996    739,401    1,515,973 
Total   $1,146,699   $1,446,917   $3,629,167   $4,562,604 

 

11

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Sales by customer type:  2026   2025   2026   2025 
   Three Months Ended September 30,   Nine Months Ended September 30, 
Sales by customer type:  2026   2025   2026   2025 
Governmental   $1,026,863    1,129,056   $2,966,246   $3,461,120 
Non-governmental    119,836    317,861    662,921    1,101,484 
Total   $1,146,699    1,446,917   $3,629,167   $4,562,604 

 

Emergency preparedness

 

We provide comprehensive services primarily to state and local governments. These services include managing their building sites, medical stockpiles of equipment, supplies and responding to state or local emergencies. We also provide Quality Control/Assurance to safeguard vaccines, medical supplies, and equipment. Revenue is recognized when services are rendered, or medical supplies are shipped or delivered.

 

Specialty Packaging

 

Our specialty temperature-regulating packaging solutions provide a better thermal system to maintain and protect products and ensure peak customer experience. In utilizing this packaging, customers yield the benefits of lower costs and overhead while improving process, agility, velocity, accuracy, and repeatability of complex fulfillment networks. Revenue is recorded when products are delivered, or services are rendered. Additionally, it also includes amounts billed to customers related to shipping and handling are classified as revenue and the Company’s shipping and handling costs are included in costs of revenues as well as the Company’s contract with a customer for cloud-based temperature monitoring software. The customer paid their contract in advance and therefore revenue is earned monthly over the term of the contract.

 

Stock Warrants

 

During the first quarter ended March 31, 2025, the Company granted 72,179 stock warrants to various individuals of the underwriting firm that assisted the Company with its initial public offering on February 4, 2025. The stock warrants were issued in lieu of cash for a portion of their services. There were no warrants issued during the third quarter ended September 30, 2026. The Company accounts for its warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, “Distinguishing Liabilities from Equity” and ASC 815, “Derivatives and Hedging”. The assessment considers whether the warrants are freestanding financial instruments that would require classification as a liability under ASC 480, as well as whether the warrants qualify for equity classification or require liability classification after consideration of the guidance and criteria outlined in ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions that impact classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance. For issued warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. As of September 30, 2026, the Company’s condensed consolidated balance sheet included equity classified warrants, reported as additional paid in capital.

 

12

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Stock-Based Compensation

 

The Company provides stock-based compensation to its employees, professional service vendor and Board of Directors. The Company is required to exercise judgment and make estimates when determining the (i) fair value of each award granted and (ii) projected number of awards expected to vest. The Company calculates the fair value of all stock-based awards at the date of grant using the Black-Scholes option-pricing model for stock options, date of grant using the common stock price for restricted stock units and Monte Carlo simulation model for market-based awards. The Company uses the straight-line method to amortize this fair value as compensation cost over the requisite service period. Any forfeitures are recognized as they occur.

 

Net Loss per Common Share

 

The following table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share because their effect was anti-dilutive for the nine months ended September 30, 2026 and September 30, 2025:

 

   (Unaudited) 
   Nine Months Ended September 30, 
   2026   2025 
Stock Options   1,175,000    1,187,500 
Restricted Stock Awards   487,500    493,750 
Stock Warrants   72,179    72,179 
Contingently shares issuable under ELOC Facility (settlement shares)   288,744    - 
Total   2,023,423    1,753,429 

 

 

Under the ELOC Facility, the Company delivers pre-settlement shares upon each purchase notice, and a variable number of additional shares to be settled after the reporting period. Pre-settlement shares are included in basic net loss per share and the additional shares above the pre-settlement shares are contingently issuable shares: they are excluded from basic net loss per share until the final number of shares to be delivered and all necessary conditions are satisfied. Because the Company reported a net loss, these shares were anti-dilutive and excluded from diluted net loss per share.

 

Cost of Revenues

 

Our cost of revenue primarily includes the amounts paid to outside service providers, monitoring, direct and indirect labor, warehouse rent and other related expenses.

 

Advertising Expense

 

Advertising costs primarily consist of trade shows, other promotional expenses and the cost to retain our marketing firm. Advertising costs are expensed as incurred. Advertising expense for the three months ended September 30, 2026 and 2025 was $543,700 and $201,599, respectively. Advertising expense for the nine months ended September 30, 2026 and 2025 was $662,799 and $491,148, respectively.

 

13

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Fair Value of Financial Instruments

 

The Company accounts for its derivative instruments in accordance with the provisions of Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging, which, among other things, establishes accounting and disclosure requirements for derivative instruments. The fair value of the instruments under ASC 820-10, Fair Value Measurement, which among other things provides the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I measurement) and the lowest priority to unobservable inputs (Level III measurements). The three levels of fair value hierarchy under ASC 820-10, Fair Value Measurement, are as follows:

 

Level I - Quoted prices are available in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

 

Level II - Significant observable inputs other than quoted prices in active markets for which inputs to the valuation methodology include: (1) Quoted prices for similar assets or liabilities in active markets; (2) Quoted prices for identical or similar assets or liabilities in inactive markets; (3) Inputs other than quoted prices that are observable; and (4) Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level II input must be observable for substantially the full term of the asset or liability.

 

Level III - Significant unobservable inputs that reflect an entity’s own assumptions that market participants would use in pricing the assets or liabilities.

 

The asset or liability fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

 

The Company’s financial instruments primarily consist of cash and cash equivalents, accounts receivable, accounts payable and derivative liabilities.

 

The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable approximate their respective fair values because of the short-term maturities or expected settlement dates of these instruments.

 

The derivative liability as of September 30, 2026 and December 31 2025 are $754,000 and $371,216, respectively and are valued using a Monte Carlo simulation model utilizing a variety of inputs and assumptions such as volatility, risk-free rates, volume weighted average price and cash flow assumptions. This is considered a Level III valuation technique. Please see Note 7, “Equity – Equity Line of Credit” for information on these assumptions and fair value of this derivative liability as of September 30, 2026. There were no transfers in or out of Level 3 from other levels in the fair value hierarchy for the three and nine months period ended September 30, 2026.

 

   September 30, 2026   Level 1   Level 2   Level 3 
Derivative liability at fair value   $754,000   $—   $—   $754,000 
Total liability measured at fair value   754,000    —    —    754,000 

 

14

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Income Tax

 

The Company provides for income taxes and the related accounts under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates expected to be in effect during the year in which the basis differences reverse. Valuation allowances are established when management determines it is more likely than not that some portion, or all, of the deferred tax assets will not be realized.

 

Leases

 

The Company’s leases predominantly relate to real estate and equipment, such as vehicles and industrial equipment utilized in operations. Contracts are reviewed at inception to determine if the arrangement is a lease. The Company generally enters into long-term real estate leases with one to ten-year terms. In the normal course of business, the Company also enters into short-term leases having terms of one year or less. These leases are generally equipment leases entered into for short periods of time (e.g., daily, weekly, or monthly) to satisfy immediate and/or short-term operational needs of the business which can arise based upon the nature of particular services performed. The Company has elected not to recognize right-of-use (“ROU”) assets and lease liabilities for these short-term leases. Operating leases with terms exceeding one year are recognized as ROU assets and lease liabilities and measured at the commencement date based on the present value of the future lease payments over the lease term. Certain of the Company’s real estate leases contain escalating future lease payments. Escalating lease payments that are based upon explicit amounts contained in the lease or an index (e.g., consumer price index) are included in the Company’s determination of future lease payments to determine the ROU asset and lease liability recognized at the commencement date. Any differences in the future lease payments from initial recognition are not anticipated to be material and will be recorded as variable lease cost in the period incurred. The variable lease cost will also include the Company’s portion of property tax, utilities, and common area maintenance. A significant portion of the Company’s real estate lease agreements include renewal periods at the Company’s option. The Company includes these renewal periods in the lease term only when renewal is reasonably certain based upon facts and circumstances specific to the lease and known by the Company. The Company uses its incremental borrowing rate available at the lease commencement date in determining the present value of future lease payments as the implicit rate is typically not readily determinable. For operating leases, lease cost is recognized on a straight-line basis over the lease term and is included in cost of revenues or selling, general and administrative expenses depending on the use of the asset. As of September 30, 2026 and December 31, 2025, the Company did not have any leases that were classified as finance leases.

 

15

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Recent Accounting Pronouncements

 

In November 2024, the FASB issued ASU 2024-03, Income Statement Reporting-Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses. The standard update improves the disclosures about a public business entity’s expense by requiring more detailed information about certain types of costs and expenses in the notes to the financial statements. The guidance will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The standard updates are to be applied prospectively, with the option to apply them retrospectively. We are currently evaluating the impact of the new standard’s disclosure requirements on our financial statements.

 

In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This standard introduces a practical expedient for the application of the current expected credit loss (“CECL”) model to current accounts receivable and contract assets. ASU 2025-05 is effective for annual periods beginning after December 15, 2025 and interim periods within those annual periods. The Company adopted ASU 2025-05 for the fiscal year and interim period beginning January 1, 2026 and elected the practical expedient. The adoption did not have a material impact on the consolidated financial statements and related disclosures.

 

In December 2025, the FASB issued ASU No. 2025-11, “Interim Reporting – Narrow-Scope Improvements,” which is intended to improve the navigability of previous guidance and clarify when that guidance is applicable. Among other items, it establishes a principle under which an entity must disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is not intended to change the fundamental nature of interim reporting or expand or reduce current interim disclosure requirements. The guidance may be applied retrospectively or prospectively and will be effective for the Company for interim periods beginning in fiscal year 2028. The Company is currently evaluating the impact of this ASU but does not anticipate this adoption to have a material impact on the Company’s financial statements.

 

The FASB issues ASUs to amend the authoritative literature in ASC. There have been a number of ASUs to date, including those above, that amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact on our consolidated financial statements.

 

16

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 3- ACCRUED EXPENSES

 

Accrued expenses consist of the following:

  

   (Unaudited)     
   September 30,   December 31, 
   2026   2025 
Payroll and related costs  $217,606   $149,312 
Credit card   45,206    14,348 
Professional Fees   494,748    113,139 
Insurance   -    145,227 
Storage   49,428    46,872 
Other   3,345    33,285 
Total  $810,333   $502,183 

 

NOTE 4 – LINE OF CREDIT

 

On July 29, 2026, Coldchain Technology Services, LLC (“CTS”), a subsidiary of the Company, entered into a Business Loan Agreement and Promissory Note with First United Bank and Trust Co (the “Lender”) providing for a $1,000,000 non-revolving line of credit (the “Line of Credit”). Proceeds of the Line of Credit are used for working capital. The Line of Credit originally matured on October 29, 2026. The Company and First United Bank and Trust Co agreed to extend the maturity date of the Line of Credit by 90 days, from October 29, 2026 to January 27, 2027. All other terms of the Line of Credit remain unchanged.

 

Borrowings under the Line of Credit bear interest at a variable rate equal to the Wall Street Journal prime rate plus 0.50%, subject to a floor of 6.00%, computed on the basis of a 360-day year for the actual number of days outstanding. Interest is payable monthly, beginning August 29, 2026. Upon an event of default, including failure to pay at maturity, the interest rate increases to 18.00%. A late charge of 5.00% of the unpaid portion of a regularly scheduled payment applies to payments more than 10 days late. CTS may prepay the Line of Credit at any time without penalty; however, loan fees are earned in full at closing and are non-refundable.

 

The Line of Credit is secured by a first-priority security interest in substantially all of CTS’s inventory, chattel paper, accounts, equipment and general intangibles. In addition, the Line of Credit is secured by (i) a pledge of an investment account owned by The Sandra G. Croyle Living Trust and (ii) The Line of Credit is also guaranteed, on an unlimited basis, by four individuals who are related parties of the Company by virtue of their ownership interest and management roles with the company. The Line of Credit is further secured by the CEO’s personal deposit account and an investment account held by a trust of which management personnel is a trustee. The Company did not pay any consideration to the guarantors or the collateral providers in connection with these arrangements (Note 5).

 

The Line of Credit Agreement contains customary affirmative and negative covenants. CTS must (i) deliver quarterly financial statements with schedules within 45 days of each quarter-end and annual tax returns, (ii) obtain the Lender’s approval before incurring additional debt, (iii) maintain its primary operating deposit accounts with the Lender within 90 days of closing, and (iv) obtain the Lender’s consent before merging, consolidating, changing its business, selling collateral outside the ordinary course of business, or making distributions with respect to its capital accounts. Events of default include nonpayment, breach of covenants, defaults under other agreements, a material adverse change in the financial condition of CTS or any guarantor, and the Lender’s good-faith belief that it is insecure. Upon an event of default, the Lender may declare all amounts immediately due and payable. As of September 30, 2026, the Company was in compliance with all covenants under the Loan Agreement.

 

During the three months ended September 30, 2026, CTS borrowed $1,000,000 under the Line of Credit, no further amounts were available to borrow. The outstanding balance is included in current liabilities in the condensed consolidated balance sheet. The weighted-average interest rate on borrowings outstanding under the Line of Credit at September 30, 2026 was 7.25%.

 

During the three and nine months ended September 30, 2026, the Company recognized and paid interest expense of $10,482 under the Line of Credit. Fees paid to the lender in connection with the Line of Credit were immaterial and recognized as expense during the three months ended September 30, 2026. There were no borrowings outstanding prior to fiscal year 2026.

 

17

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 5 – RELATED PARTY TRANSACTIONS

 

Business Partner

 

Health Hero America (“HHA”) is a related party by virtue of common ownership of the Company. There were no transactions with the related party during the three months ended September 30, 2026. During the nine months ended September 30, 2026, the Company provided certain labor services to HHA and recognized service revenue amounting to $5,162, all of which was recognized during the three months ended March 31, 2026. As of September 30, 2026 and December 31, 2025, receivables arising from this transaction amounted to $4,342 and $16,789, respectively.

 

Cold Chain Delivery Systems (“ CCDS”), who is a related party by virtue of common ownership of the Company. There were no transactions with the related party during the three and nine months ended September 30, 2026 and 2025. As of September 30, 2026, and December 31, 2025, the Company has $0 owed to this related party.

 

Outlaw Run Ranch (“ORR”) is a related party by virtue of common ownership of the Company. The Company pays $9,800 per month to ORR for rent expense. As of September 30, 2026, and December 31, 2025, the Company has $0 owed to this related party. As of September 30, 2026 and December 31, 2025, operating lease liability relating to such lease agreement with this related party amounted to $327,518 and $389,630, respectively. See Note 9 for other key terms of the lease agreement.

 

Warehouse Asset Management is a related party by virtue of common ownership. The Company leases its headquarters, warehouse, other warehouse equipment and a box truck for $15,425 per month. As of September 30, 2026, and December 31, 2025, the Company has $0 owed to this related party. As of September 30, 2026 and December 31, 2025, operating lease liability relating to such lease agreement with this related party amounted to $524,042 and $625,805, respectively.

 

During the three months ended March 31, 2025 the Company awarded 100,000 stock options to the CEO’s son as compensation for services rendered in a prior period and is subject to the same vesting condition as the Company’s other stock option awards. 87,500 stock options have vested and are fully exercisable as of September 30, 2026 and 12,500 remain unvested. The key terms and fair value inputs and assumptions utilized for this stock option are disclosed in Note 8. The Company recognized $28,375 as an expense for the three months ended September 30, 2026 and 2025. The Company recognized $85,125 and $72,073 as an expense for the nine months ended September 30, 2026 and 2025, respectively.

 

Monarch Property Management is a related party by virtue of common ownership of the Company. The Company paid for certain legal expenses, which amounted to $9,430 and $59,491 during the three and nine months ended September 30, 2026. As of September 30, 2026 and December 31, 2025, the Company is owed $59,491 and $0 by this related party, respectively, and is presented as a part of Advances to Affiliate in the Company’s condensed consolidated balance sheet. The Company expects to collect the Advances to Affiliate, however there is an uncertainty to the timing of such collection.

 

In connection with the $1,000,000 Line of Credit entered into by Coldchain Technology Services, LLC (“CTS”), a subsidiary of the Company, with First United Bank and Trust Co on July 29, 2026 (see Note 4), The Line of Credit is guaranteed, on an unlimited basis, by four individuals who are related parties of the Company by virtue of their ownership interests and management roles of the Company. The Line of Credit is further secured by the CEO’s personal deposit account and an investment account held by a trust of which management personnel is a trustee.

 

The Company has performed an analysis under ASC 810 and has determined that the afore-mentioned related parties do not qualify as a Variable Interest Entity and therefore those entities were not consolidated in the preparation of the accompanying financial statements.

 

18

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 6 - SEGMENTS

 

Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the Company’s Chief Operating Decision Maker (“CODM”) to make decisions with respect to resource allocation and assessment of performance. To date, the Company has viewed its operations and manages its business as one operating segment. The results of its operating segment are reviewed monthly by the Company’s Chief Executive Officer and President, who has been identified as the CODM.

 

The CODM regularly assesses the performance of the 1single operating segment and reporting segment and decides how to allocate resources based on net income calculated on the same basis as net income reported in the Company’s statements of operations. The CODM is also regularly provided with expense information at a level consistent with that disclosed in the Company’s statements of operations.

 

NOTE 7 - EQUITY

 

During February 2025, we completed our initial public offering (“IPO”) of 1,280,000 shares of common stock at a price of $4.00 per share, generating gross proceeds of $5,120,000. Additionally, the underwriters partially exercised their over-allotment option (the “green shoe”), purchasing approximately 164,000 shares at $4.00, resulting in additional gross proceeds of approximately $656,000. In total, the offering generated gross proceeds of approximately $5,776,000. After deducting underwriting discounts and commissions of approximately $1,000,000, we received net proceeds of approximately $4,700,000. In connection with the offering, we issued to the underwriters warrants to purchase up to 72,179 shares of our common stock at an exercise price of $4.80 per share for a total value of $144,358. These warrants have a term of five years from the effective date of the registration statement. We also incurred $188,832 of offering costs.

 

19

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 7 – EQUITY (Continued)

 

During the nine months ended September 30, 2026, the Company did not complete any public offerings of its common stock. Equity activity during the quarter consisted of (i) the issuance of 906,000 shares of common stock pursuant to the Equity Line of Credit (“ELOC”) Facility, as described below; These issuances include shares issued in connection with ELOC drawdowns during the quarter. (ii) the issuance of 18,750 restricted stock units on September 30, 2026 upon the vesting of restricted stock units (“RSUs”) held by the Company’s three nonemployee directors (6,250 shares each). During the three months ended September 30, 2026, 2,400 RSUs were forfeited in connection with the departure of one director, resulting in 16,350 RSUs vesting on September 30, 2026.; and (iii) the issuance of 87,500 shares of common stock on July 30, 2026 under the company’s Stock Option Plan as equity compensation for legal and consulting services provided by third party. The shares were fully vested when issued and were valued at $129,499, or $1.48 per share on the grant date. The Company recognized $129,499 of expense related to this issuance during the three and nine months ended September 30, 2026. During the nine months ended September 30, 2026, the Company issued a total of 1,674,705 shares of common stock under the ELOC Facility and 53,850 shares of restricted common stock upon the vesting of director RSUs.

 

As of September 30, 2026, the Company had the following equity awards outstanding:

 

●Stock options: 1,175,000 options outstanding under the Company’s equity incentive plan, During the nine months ended September 30, 2026, the Company granted 100,000 options, and 112,500 options were forfeited upon an executive’s resignation.
●RSUs: 75,000 RSUs granted on January 1, 2026 to the three non-employee directors, vesting quarterly through December 31, 2026. Of these, 53,850 had vested and 12,500 remained unvested. 8,650 shares were forfeited upon a director’s resignation.
●Performance-based RSUs: 225,000 outstanding, none of which had vested or been expensed as of September 30, 2026 because the performance conditions were not considered probable.
●Market-based RSUs: 250,000 outstanding, vesting upon achievement of specified company valuation targets.
●Underwriter warrants: 72,179 warrants issued in February 2025 with a five-year term and an exercise price of $4.80 per share.

 

All outstanding RSUs, options and warrants remain subject to applicable vesting, lock-up and control restrictions.

 

Equity Line of Credit (ELOC)

 

On July 24, 2025, the Company entered into an ELOC Purchase Agreement (“Equity Line of Credit,” or the “ELOC Facility”) with an investor, whereby the Company has the right, but not the obligation, to sell to the investor therein, up to an aggregate of $25.0 million of shares of the Company’s common stock, par value $0.001 per share, subject to the terms and conditions set forth therein. The Purchase Agreement has a term ending on the earlier of (i) the first day of the month following the 18-month anniversary of the Commencement Date or (ii) the date the Investor has purchased the shares equal to the agreed investment amount. During the term, the Company may, at its discretion, deliver either Regular Purchase Notices for $500,000 to $2,000,000 per notice or Exempt Purchase Notices of up to $1,000,000 per notice. Each Regular Purchase is priced at 95% of the lowest daily VWAP during the applicable measurement period (or 80% if the Company’s stock is not trading on the Nasdaq Capital Market). In connection with each Regular Purchase, the Company will provide an estimate of the number of the shares deliverable, based on 90% of the prior day’s closing price. Each Exempt Purchase is priced similarly with an incremental 10% shares to be issued.

 

In January 2026, the Company issued 171,868 shares of common stock as final settlement shares related to an ELOC raise initiated during the third quarter of 2025. These shares were issued pursuant to the contractual settlement provisions of the ELOC facility and did not result in additional cash proceeds during the current period.

 

20

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 7 – EQUITY (Continued) 

 

On March 10, 2026, the Company entered into an amendment to its ELOC Facility wherein it extended the maturity to April 1, 2027. Additionally, certain amendments to the measurement period and the settlement price from 95% of the lowest daily VWAP to 95% of lowest closing price during the measurement period.

 

On August 18, 2026, the Company and the ELOC Investor entered into a First Amended and Restated Purchase Agreement (the “Restated Purchase Agreement”), which amends and restates in its entirety the ELOC Facility, as previously amended. The Restated Purchase Agreement, among other changes: (i) increases the aggregate amount of common stock the Company may sell from $25.0 million to $75.0 million (the “Available Amount”); (ii) provides that each Regular Purchase and each Exempt Purchase may be for $500,000 to $2,000,000 per notice; (iii) prices each Regular Purchase at 95% (or 75% if the common stock is suspended from trading or delisted from the Nasdaq Capital Market) of the lowest daily trading price during the applicable measurement period, and each Exempt Purchase at 90% (or 80% if suspended or delisted) of the lowest daily trading price during the applicable measurement period, with the incremental 10% of shares previously issuable on Exempt Purchases eliminated; (iv) defines the measurement period as beginning when the ELOC Investor receives the purchase notice and ending on the trading day on which the aggregate dollar volume of common stock traded equals 5x the purchase amount, subject to a minimum of five trading days for Regular Purchases and three trading days for Exempt Purchases; and (v) limits the ELOC Investor’s monthly resales of common stock to the greater of $25,000 per trading day and 20.0% of the daily trading volume. The pricing applicable to a Regular Purchase is automatically reduced to 75% while an event of default is continuing. For each purchase, the Company delivers pre-settlement shares based on 90% of the prior day’s closing price, and a final settlement of shares is made after the measurement period ends, such that the total shares delivered equal the purchase amount divided by the applicable purchase price. The ELOC Investor may not beneficially own more than 4.99% of the Company’s outstanding common stock, and the Company may not deliver a purchase notice when the closing price of its common stock is below a floor price of $1.00. The Company agreed not to enter into other variable-priced equity or equity-linked financings, other than certain exempt issuances, while the Restated Purchase Agreement is in effect. No additional commitment shares were issued in connection with the Restated Purchase Agreement; 15,000 commitment shares were issued under the original agreement in 2025. Management evaluated the accounting effects of the August 18, 2026 amendment and concluded that it does not change the Company's previous accounting conclusions. The ELOC Facility continues to be accounted for as a derivative liability measured at fair value, with changes in fair value recognized in earnings.

 

During the nine months ended September 30, 2026, the Company issued shares of common stock pursuant to the Equity Line of Credit (“ELOC”) facility in connection with both current-period drawdowns and the final settlement of ELOC activity initiated in a prior period. On August 20, 2026, the Company delivered an Exempt Purchase Notice to the ELOC Investor for $2,000,000. The pre-settlement shares were delivered in tranches: 296,000 shares on August 20, 2026, 300,000 shares on August 27, 2026 and 310,000 shares on September 14, 2026, for a total of 906,000 shares during the three months ended September 30, 2026. During the three months ended September 30, 2026, the Company received net proceeds of $1,815,000 from this draw, which is net of third-party fees of $185,000 that are reflected as ELOC facility transaction expenses in the condensed consolidated statements of operations. Subsequent to September 30, 2026, on October 8, 2026, the Company issued the remaining 288,744 shares, bringing the total shares issued for this draw to 1,194,744. Refer to Note 10 Subsequent Events.

 

The Company has the right to terminate the ELOC Facility at any time after the Commencement Date, for any reason or for no reason by delivering notice to the Investor electing to terminate the agreement without any liability except in the event the Company has sold less than $7,500,000 to the Investor, the Company shall pay an additional fee of $250,000 that is payable either in cash or in shares of Common Stock at a price equal to 100% of the Closing Price on the date immediately preceding the date of receipt by the Investor of the Company Termination Notice. The ELOC Facility will also automatically terminate upon reaching the $75,000,000 Available Amount or at the Maturity Date without any action or notice on the part of any party and without any liability whatsoever of any party to any other party under the ELOC Facility.

 

21

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 7 – EQUITY (Continued)

 

Equity Line of Credit (ELOC) (Continued)

 

The ELOC Facility contains customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.

 

The Company accounted for its ELOC Facility as a purchased put option and is either equity-classified or liability-classified instruments based on an assessment of the agreement’s specific terms and applicable authoritative guidance in ASC 480, “Distinguishing Liabilities from Equity” and ASC 815, “Derivatives and Hedging”. The assessment considers whether the purchased put option is a freestanding financial instrument that would require classification as a liability under ASC 480, as well as whether the purchased put option would qualify for equity classification or require a liability classification after consideration of the guidance and criteria outlined in ASC 815, including whether the purchased put option are indexed to the Company’s own common shares and whether the holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions that impact classification. The Company also assessed embedded features in the ELOC Facility under the ASC 480 and ASC 815 guidance, management believed that these embedded features were not freestanding and are clearly and closely related to the host contract and as such do not require bifurcation from the purchased put option. This assessment, which requires the use of professional judgment, is conducted at the time of agreement. The Company assessed that the purchased put option is not under the scope of ASC 480 but is a derivative liability under ASC 815 as it does not meet the scope exception, indexation guidance and equity classification criteria under ASC 815 due to certain variability to the settlement price. As such, the Company accounted for the purchased put option as a derivative liability recognized at fair value at the inception date and each reporting period.

 

The fair value of the purchased put option was estimated on the date of agreement using Monte Carlo Simulation Model with the following assumptions at each measurement date:

 

   Inception Date   September 30, 2026 
Expected life (in years)   1.52    0.5 
Expected stock price volatility   50.5%   65.0%
Risk-free interest rate   4.00%   4.30%
Stock Price   5.28    2.43 

 

The risk-free interest rate was based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of purchased put option. Expected volatility was derived using the Company’s peer volatility calculated from its peer companies’ volatilities over the time period commensurate with the expected life of the purchased put option. The expected life was calculated using the terms of the ELOC Facility.

 

22

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 7 – EQUITY (Continued)

 

Equity Line of Credit (ELOC) (Continued)

 

The Company recognized the fair value of the purchased put option as of September 30, 2026, in its balance sheet under the caption, “Derivative Liability.” The change in the fair value of the Derivative Liability during the nine months ended September 30, 2026, was $382,784 and was recognized in the Company’s condensed consolidated statements of operations.

 

   September 30, 2026   December 31, 2025 
Derivative liability at fair value – beginning balance   371,216    - 
Recognition of derivative liability arising from ELOC facility        974,309 
Changes in fair value of derivative liability during the period   382,784    (603,093)
Derivative liability at fair value – ending balance  $754,000   $371,216 

 

The derivative liability related to the ELOC Facility, the Company’s only Level 3 financial instrument measured at fair value on a recurring basis, was $588,604 as of June 30, 2026. During the three months ended September 30, 2026, the Company recorded a $165,396 increase in the fair value of the liability, reported as a loss in “Changes in fair value of derivative liability” in the condensed consolidated statements of operations, resulting in a balance of $754,000 as of September 30, 2026.

 

Registration Rights Agreements

 

In connection with the ELOC Facility, the Company also granted the Investor certain registration rights for shares of common stock issuable within the ELOC Facility, including (a) the ability of a holder to request that the Company file a Form S-1 registration statement; (b) the ability of a holder to request that the Company file a Form S-3 registration statement with respect to outstanding registrable securities if at any time the Company is eligible to use a Form S-3 registration statement; and (c) certain piggyback registration rights related to potential future equity offerings of the Company, subject to certain limitations.

 

On August 18, 2026, the Company restated the original agreement through the First Amended and Restated Registration Rights Agreement. The Company is required to file a new registration statement covering the resale of the additional shares issuable under the increased $75.0 million Available Amount within 30 days of August 18, 2026. It must also have that registration statement declared effective by the earlier of (i) the 60th calendar day after the amendment date, or the 90th calendar day if the SEC conducts a full review, and (ii) the second business day after the SEC notifies the Company that the registration statement will not be reviewed. If the Company fails to timely file the registration statement or to have it declared effective by the applicable deadline, it must issue 25,000 shares of common stock to the ELOC Investor within two trading days of each failure. The share issuance is not the investor’s exclusive remedy.

 

On August 24, 2025, the Company filed a registration statement on Form S-1 related to the resale, from time to time, of up to 6,000,000 shares of Common Stock in connection with the ELOC Facility. The Registration Statement on Form S-1 was declared effective September 22, 2025.

 

ATM Offering Program

 

On May 26, 2026, the Company entered into an At-The-Market (“ATM”) Issuance Sales Agreement, pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $5.0 million. Sales, if any, may be made from time to time through an underwriter in transactions deemed to be “at the market offerings” under Rule 415 of the Securities Act, including sales on The Nasdaq Capital Market or other existing trading markets. The Company may be responsible to pay a commission to the counterparty equal to 3.0% of the gross proceeds from shares sold under the agreement, and the Company intends to use any net proceeds for working capital and general corporate purposes. As of September 30, 2026, no shares had been sold under the ATM program and the Company had not received any proceeds therefrom.

 

In connection with the establishment of the ATM program, the Company incurred approximately $75,000 of legal, accounting, filing, and other direct incremental offering costs. These costs have been capitalized as deferred offering costs and are included within the condensed consolidated balance sheets. The deferred offering costs will be reclassified as a reduction of additional paid-in capital upon future sales of common stock under the ATM program.

 

NOTE 8 - SHARE BASED COMPENSATION

 

Overview

 

The Company grants share-based compensation awards to the Company’s employees as provided by the 2024 Equity Incentive Plan (“2024 Plan”), which was approved by the Company’s stockholders on October 24, 2024. The 2024 Plan provides that grants may be in any of the following forms: incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, and performance awards. The 2024 Plan will be administered and interpreted by the Compensation Committee of the Board of Directors. The Compensation Committee has the authority to determine the individuals to whom grants will be made under the 2024 Plan, determine the type, size and terms of the grants, determine the time when grants will be made and the duration of any applicable exercise or restriction period (subject to the limitations of the 2024 Plan) and deal with any other matters arising under the 2024 Plan. All the employees of the Company and its subsidiaries are eligible for grants under the 2024 Plan. Non-employee directors and consultants of the Company are also eligible to receive grants under the 2024 Plan.

 

23

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 8 - SHARE BASED COMPENSATION (CONTINUED)

 

Overview (Continued)

 

The Company has reserved 2,000,000 shares of common stock for the granting of such awards. During the three and nine months ended September 30, 2026, the Company recognized share-based compensation expense of $271,238 and $979,817, respectively. During the three and nine months ended September 30, 2025, the Company recognized share-based compensation expense of $404,915 and $1,154,842, respectively. As of September 30, 2026, the Company has recognized $2,539,573 in share-based compensation expense since initial issuance in February 2025. Share-based compensation expense is recorded in selling, general and administrative expenses on the condensed consolidated statement of operations.

 

During the three months and nine months ended September 30, 2026, the Company entered into a professional service agreement with a third party wherein, 87,500 shares of common stock were issued on July 30, 2026 as compensation. The Company recognized $129,499 of professional fee expense, which is included in selling, general and administrative expenses.

 

Stock Options

 

During the nine months ended September 30, 2026, the Company granted 100,000 non-statutory stock options to an executive employee, pursuant to their employment agreement, with 50,000 stock options immediately vested and the remaining options vesting in equal quarterly installments over a 12-month period by March 31, 2027. As of September 30, 2026, 75,000 of the options have vested. The options were granted under the Company’s equity incentive plan and are subject to the same terms and conditions, including forfeiture provisions, as the Company’s other stock option awards. The award is included in the stock option activity tables presented below.

 

During the nine months ended September 30, 2026, a certain former employee of the Company forfeited all of their remaining unvested options. As the Company has elected to record forfeitures as they occur, the Company recognized a related reversal of its previously recognized compensation expense for unvested stock option awards of $22,322 as a reduction to stock compensation expense for the period.

 

A summary of nonstatutory stock option activity during the nine months ended September 30, 2026 is included below.

 

  

Number of

Awards

  

Weighted-

Average

Exercise

Price

  

Weighted-

Average

Remaining

Contractual

Term (in

years)

  

Aggregate

Intrinsic

Value

 
Outstanding at December 31, 2025   1,187,500    4.00    9.1         - 
Granted   100,000    1.82    9.98    - 
Exercised   -    -    -    - 
Forfeited   -    -    -    - 
Outstanding at March 31, 2026   1,287,500    3.83    8.95    - 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Forfeited   (112,500)   2.27    -    - 
Outstanding at June 30, 2026   1,175,000    3.98    8.70    - 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Forfeited   -    -    -    - 
Outstanding at September 30, 2026   1,175,000    3.98    8.45    - 
                     
Outstanding and Exercisable   900,000    3.98    8.45    - 

 

24

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 8 - SHARE BASED COMPENSATION (CONTINUED)

 

The fair value of each option granted was estimated on the date of grant using the Black-Scholes-Merton option-pricing model with the following assumptions:

 

   2026   2025 
Expected life (in years)   5.17    5.66 
Expected stock price volatility   46.53%   49.20%
Risk-free interest rate   4.52%   4.19%
Dividend rate   0.00%   0.00%

 

The risk-free interest rate was based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. Expected volatility was derived using the Company’s peer volatility calculated from its peer companies’ volatilities over the time period commensurate with the expected life of the stock options. The expected life for the stock options granted was calculated using the midpoint assumption equal to the time from the grant date to the midpoint of the weighted average vesting date and the expiration date. The Company does not currently pay dividends on its common stock nor does it expect to in the foreseeable future.

 

The weighted average grant date fair value of options granted during the nine months ended September 30, 2026 was $0.89 per share. As of September 30, 2026, there was $374,870 of unrecognized expense for unvested stock options that is expected to be recognized over a weighted average period of less than one year. During the three months ended September 30, 2026 and September 30, 2025, the Company recognized share-based compensation expense of $252,566 and $326,313, respectively. During the nine months ended September 30, 2026 and September 30, 2025, the Company recognized share-based compensation expense of $916,055 and $919,744, respectively. These amounts are recorded in selling, general and administrative expenses on the condensed consolidated statement of operations.

 

Performance-Based Awards

 

During the nine months ended September 30, 2025, the Company granted 225,000 performance-based stock awards to its Chief Executive Officer. The grant date fair value was $4.00 per share. The vesting is subject to the Company meeting certain business and financial goals by October 15, 2026. As of September 30, 2026, none of the performance-based awards were probable of vesting and thus no expense was recognized during the three months and nine months ended September 30, 2026 and 2025. All the awards are expired.

 

Market-Based Awards

 

During the nine months ended September 30, 2025, the Company granted 250,000 market-based stock awards to its Chief Executive Officer. The weighted average grant date fair value was $0.04 per share, which was calculated using a Monte Carlo simulation model. The vesting is subject to the Company meeting certain market-based targets by October 15, 2026. The Company recognized $345 and $3,425 of expense related to these market-based awards for the three months ended and the nine months ended September 30, 2026, respectively.

 

The fair value of each market-based awards granted was estimated on the date of grant using a Monte Carlo pricing model with the following assumptions:

 

  

Grant date

 
Derived service period (years)   1.44 – 1.48 
Dividend rate   -%
Risk-free interest rate   4.08%
Expected stock price volatility   41.56%

 

The risk-free interest rate was based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the market-based awards. Expected volatility was derived using the Company’s peer volatility calculated from its peer companies’ volatilities over the time period commensurate with the expected life of the market-based awards. The expected life for the market-based awards granted was calculated using the midpoint assumption equal to the time from the grant date to the midpoint of the weighted average vesting date and the expiration date. The Company does not currently pay dividends on its common stock nor does it expect to in the foreseeable future.

 

25

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 8 - SHARE BASED COMPENSATION (CONTINUED)

 

Market-Based Awards (Continued)

 

   Performance-Based   Market-Based 
  

Number of

Awards

  

Weighted-

Average Grant

Date Fair Value

  

Number of

Awards

  

Weighted-

Average Grant

Date Fair Value

 

Outstanding at January 1, 2026

   225,000   $4.0    250,000   $0.04 

Granted

   -    -    -    - 
Change in units based on performance   -    -    -    - 
Forfeited   -    -    -    - 
Outstanding at March 31, 2026   225,000   $4.0    250,000   $0.04 
Granted   -    -    -    - 
Change in units based on performance   -    -    -    - 
Forfeited   -    -    -    - 
Outstanding at June 30, 2026   225,000   $4.00    250,000   $0.04 
Granted   -    -    -    - 
Change in units based on performance   -    -    -    - 
Forfeited   -    -    -    - 
Outstanding at September 30, 2026   225,000   $4.00    250,000   $0.04 

 

Restricted Stock Units

 

During the nine months ended September 30, 2026, the Company granted 75,000 restricted stock units (“RSUs”) to its Board of Directors. The RSUs were awarded at a price equal to the market price of the Company’s underlying common stock on the date of grant. One-fourth of the RSUs vests each calendar quarter of 2026. During the nine months ended September 30, 2026, the Company recognized share-based compensation expense of $60,337, which is recorded in selling, general and administrative expenses on the condensed consolidated statement of operations. A total of 53,850 RSUs have vested as of September 30, 2026. A total of 12,500 RSUs are expected to vest over the remainder of the year.

 

   September 30, 2026 
  

Number of

Awards

  

Weighted

Average Grant

Date Fair Value

 
Beginning balance  $-   $- 
Issued RSUs during the period   75,000    1.12 
Vested RSUs during the period   (53,850)   1.12 
Forfeited   (8,650)   - 
Remaining unvested RSUs  $12,500   $1.12 

 

26

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 8 - SHARE BASED COMPENSATION (CONTINUED)

 

Stock Warrants

 

The grant date fair value of the Company’s stock warrants was $2.00, which was calculated using the Black-Scholes Merton option-pricing model with the following assumptions:

 

   Feb-25 
   Grant Date 
Expected life (in years)   5.0 
Expected stock price volatility   56.83%
Risk-free interest rate   4.16%
Dividend rate   0%

 

NOTE 9 - COMMITMENTS AND CONTINGENCIES

 

Operating Leases

 

The Company has various leases that expire between now and 2036. The Company’s right-of-use assets and lease liabilities primarily represent lease payments that are fixed at the commencement of a lease and variable lease payments that are dependent on an index or rate. Lease payments are recognized as lease cost on a straight-line basis over the lease term, which is determined as the non-cancelable period, including periods in which termination options are reasonably certain of not being exercised and periods in which renewal options are reasonably certain of being exercised. The discount rate is determined using the Company’s estimated incremental borrowing rate coinciding with the lease term at the commencement of a lease. The estimated incremental borrowing rate for the Company was determined to be between 3.0% - 10.6%. Rent expense for the three months ended September 30, 2026 and 2025 was $134,264 and $143,829, respectively. Rent expense for the nine months ended September 30, 2026 and 2025 was $399,913 and $400,450, respectively. Additionally, in the normal course of business, the Company enters into short-term leases having terms of one year or less. These leases are generally equipment leases and storage areas entered into for short periods of time (e.g., daily, weekly, or monthly) to satisfy immediate and/or short-term operational needs of the business which can arise based upon the nature of particular services performed. Short term lease expenses relating to these agreements amounted to $124,881 and $147,156, for the three months ended September 30, 2026 and 2025, respectively. Short term lease expenses relating to these agreements amounted to $590,469 and $384,740 for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, the weighted-average remaining operating lease term and discount rate are 6.4 years and 9.8%, respectively.

 

On October 21, 2024, the Company entered into a long-term lease agreement for corporate office space with a third party. This agreement commenced on April 1, 2025, and requires payments of $11,884 monthly, escalating 3% per annum for a term of 120 months, which ends March 31, 2035. The Company has the option to renew such lease for up to an additional one-year term. The Company accounted for such lease as operating lease as there were no purchase option nor transfer of title at the end of the lease. The Company recognized right of use assets and operating lease liabilities amounted to $988,436. Additionally, the Company was also granted a tenant improvement allowance of $280,115. The Company determined that the improvements are lessee improvements and accordingly, recognized the tenant improvement allowance as a lease incentive and a reduction to the initial recognized right of use assets and operating lease liabilities. During the nine months ended September 30, 2026, the Company received reimbursement for the $280,115 tenant improvement allowance. On October 1, 2025, the Company entered into an amendment in its long-term lease agreement for its corporate office space with a third party and extended the term from April 1, 2025 to September 30, 2035, and the rent payment will commence on October 1, 2025 rather than April 1, 2025. The Company accounted for this amendment as a lease modification. There were no changes in the lease classification as a result of this modification and the Company continues to recognize such a lease as operating lease. The Company remeasured its right of use assets and operating lease liabilities using an updated incremental borrowing rate. The change in right of use assets and operating lease liabilities related to this lease modification resulted in a decrease of $76,520 for the year ended December 31, 2025.

 

27

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 9 - COMMITMENTS AND CONTINGENCIES (Continued)

 

Operating Leases (Continued)

 

On January 1, 2025, the Company entered into an amendment in its lease agreement with a third party wherein the Company is the lessee of certain commercial property. The amendment commenced on January 1, 2025, and extended the term from May 31, 2025 to December 31, 2029, and increase in monthly rent payments from $3,650 monthly to $6,878 monthly subject to 3% increase per annum. The Company has the option to renew such lease to an additional one year term. Management determined that the renewal option is not reasonably certain to occur. The Company accounted for this amendment as a lease modification. There were no change in the lease classification as a result of this modification and the Company continues to recognize such a lease as operating lease. The Company remeasured its right of use assets and operating lease liabilities using an updated incremental borrowing rate. The change in right of use assets and operating lease liabilities related to this lease modification amounted to $324,104 for the year ended December 31, 2025.

 

On March 20, 2025, the Company entered into an amendment in its long-term lease agreement with a related party wherein the Company is the lessee of certain commercial property. The amendment commenced on April 1, 2025, and extended the term from December 31, 2025 to December 31, 2029, and increase the square footage of the leased property, a corresponding increase in monthly rent payments from $7,500 monthly to $9,800 monthly. The Company has the option to renew such lease for up to an additional six month extension and month-to-month thereafter. Management determined that the renewal option is not reasonably certain to occur. The Company accounted for this amendment as a lease modification. There were no change in the lease classification as a result of this modification and the Company continues to recognize such a lease as operating lease. The Company remeasured its right of use assets and operating lease liabilities using an updated incremental borrowing rate. The change in right of use assets and operating lease liabilities related to this lease modification amounted to $380,823 for the year ended December 31, 2025.

 

On February 24, 2026, the Company entered into a renewal lease agreement for office and storage space located in Blanco, Texas. The lease commenced on March 1, 2026 and expires on February 28, 2029, with a non-cancelable term of three years. The lease requires fixed monthly payments of $1,250 and the Company is responsible for certain utilities and other occupancy-related costs. The Company accounted for the lease as an operating lease under ASC 842. At lease commencement, the Company recognized an operating right-of-use asset of $38,737 and corresponding operating lease liabilities, measured based on the present value of future lease payments using the Company’s incremental borrowing rate at commencement. The operating lease liabilities include both current and noncurrent portions and are included within operating lease liabilities on the condensed consolidated balance sheet as of September 30, 2026.

         
   Nine months ended 
Lease cash flow information:  September 30, 2026   September 30, 2025 
         
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash flows from operating leases  $407,745   $374,925 
Total  $407,745   $374,925 

 

Summary of lease-related assets and liabilities:  September 30, 2026   December 31, 2025 
Operating lease right-of-use assets  $2,581,292   $2,582,496 
Accumulated amortization   (863,991)   (664,933)
Net operating ROU assets  $1,717,301   $1,917,563 
           
Current operating liabilities  $362,205   $323,935 
Noncurrent operating lease liabilities   1,696,980    1,663,229 
Total operating lease liabilities  $2,059,185   $1,987,164 

 

28

 

 

CALLAN JMB INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 9 - COMMITMENTS AND CONTINGENCIES (Continued)

 

Operating Leases (Continued)

 

Maturity of lease liabilities  September 30, 2026
(Unaudited)
 
October 2026 – September 2027  $551,501 
October 2027 – September 2028   558,515 
October 2028 – September 2029   556,989 
October 2029 – September 2030   259,399 
October 2030 – September 2031   165,317 
Thereafter   712,422 
Total future undiscounted lease payments   2,804,143 
Less: interest   (744,958)
Present value of lease liabilities  $2,059,185 

 

Legal Proceedings

 

The Company may be subject to legal proceedings and claims arising from contracts or other matters from time to time in the ordinary course of business.

 

Management is not aware of any pending or threatened litigation where the ultimate disposition or resolution could have a material adverse effect on its financial position, results of operations or liquidity.

 

NOTE 10 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events that occurred after September 30, 2026, through November 13, 2026.

 

Equity Line of Credit

 

Subsequent to September 30, 2026, the Company issued 288,744 additional shares of common stock to Hexstone Capital, LLC in settlement of a previously initiated $2.0 million purchase on August 20, 2026 under the Company’s Equity Line of Credit Agreement. See Note 7.

 

In October 2026, the Company also completed an additional $4.0 million sale under the ELOC, resulting in net proceeds of $3.66 million after transaction fees. The Company issued 40,000 shares of common stock at a pre-settlement purchase price of $2.178 per share, 340,000 shares of common stock at a pre-settlement purchase price of $1.04 per share, 350,000 shares of common stock at a pre-settlement purchase price of $0.72 per share, 380,000 shares of common stock at a pre-settlement purchase price of $0.39 per share and 2,586,457 shares of common stock at a pre-settlement purchase price of $0.34 per share, with additional shares issuable pursuant to the terms of the purchase agreement.

 

Nasdaq Delisting Letter

 

On October 12, 2026, the Company received a determination letter from Nasdaq stating that the Company had not regained compliance with Nasdaq Listing Rule 5550(b), which requires, among other alternatives, a minimum of $2.5 million in stockholders’ equity. The Company subsequently appealed Nasdaq’s determination. On October 15, 2026, Nasdaq acknowledged the Company’s appeal and notified the Company that the delisting action had been stayed pending a final written decision by the Nasdaq Hearings Panel. An oral hearing is scheduled for November 17, 2026. With the completed additional $4.0 million sale under the ELOC (see further discussion in the preceding paragraph), the Company believes they are in compliance with the minimum stockholders’ equity requirement of Nasdaq from the date of such sale through the date of these condensed consolidated financial statements are issued.

 

Line of Credit

 

The Company and First United Bank and Trust Co agreed to extend the maturity date of the Line of Credit by 90 days, from October 29, 2026 to January 27, 2027. All other terms of the Line of Credit remain unchanged.

 

There have been no other events or transactions during this time which would have a material effect on these consolidated financial statements.

 

Private Investment in Public Equity

 

On November 10, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors and closed a private investment of 1,363,639 shares of its common stock at a purchase price of $1.10 per share. The Company received gross proceeds of $1,500,003 for working capital and general corporate purposes. The Purchase Agreement permits the sale of up to an aggregate of $3,000,000 of shares. The shares are unregistered securities, were issued in a transaction exempt from registration and bear a restrictive legend. All of the shares were purchased by related parties of the Company.

 

Acquisitions

 

In August 2026, Callan JMB and its wholly owned subsidiary, Callan Power LLC, entered into two separate proposed acquisition transactions to acquire certain oil and gas leasehold interests and related assets. The Reger Oil agreement was signed on August 19, 2026, but the transaction did not close and was not completed. A second Asset Purchase Agreement (APA) was signed with The Pfanenstiel Company on August 26, 2026. On October 16, 2026, the Company has exercised its right to terminate the APA. As a result of the expiration and termination, neither proposed acquisition transactions were consummated.

 

NOTE 11 – Revision to June 30, 2026 Condensed Consolidated Financial Statements

 

During the preparation of the financial statements for the three and nine months ended September 30, 2026, the Company identified some revisions in the previously issued financial statements for the three and six months ended June 30, 2026. The revisions related to costs incurred in connection with a service contract performed for a customer that were previously capitalized as construction in progress rather than expensed as cost of revenue. This item was identified as part of management’s review of the financial results for the three and nine months ended September 30, 2026. The amounts of the revisions to the June 30, 2026 condensed consolidated financial statements were not deemed to be material by management.

 

The revisions to the six months ended June 30, 2026 consolidated financial statements are as follows:

 

Financial Statement Line Item 

As Previously

Reported

   Revisions   As Revised 
Cost of revenue   1,297,288    90,751    1,388,039 
Gross profit   1,185,180    (90,751)   1,094,429 
Loss from operations   (3,047,835)   (90,751)   (3,138,586)
Net loss   (4,446,977)   (90,751)   (4,537,728)
Net loss per share   (0.80)        (0.82)
                
Property and equipment, net   794,793    (90,751)   704,042 
Total assets   4,451,058    (90,751)   4,360,307 
                
Accumulated deficit   (14,706,991)   (90,751)   (14,797,742)
Total stockholders’ equity   681,863    (90,751)   591,112 

 

Financial Statement Line Item  As Previously Reported   Revisions   As Revised 
Net cash provided by (used in) investing activity   (69,481)   90,751    21,270 
Net cash used in operating activities   (2,075,943)   (90,751)   (2,166,694)

 

The revisions to the three months ended June 30, 2026 consolidated financial statements are as follows:

 

Financial Statement Line Item  As Previously Reported   Revisions   As Revised 
Cost of revenue   618,380    90,751    709,131 
Gross profit   757,946    (90,751)   667,195 
Loss from operations   (1,346,646)   (90,751)   (1,437,397)
Net loss   (1,231,923)   (90,751)   (1,322,674)
Net loss per share   (0.22)        (0.23)

29

 

 

PART II

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis is intended as a review of significant factors affecting our financial condition and results of operations for the periods indicated. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “we,” “us,” and “our” refer to Callan JMB Inc.

 

Forward-Looking Statements

 

The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in our filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements

 

Overview

 

Callan JMB is a vertically integrated logistics and fulfillment company which provides thermal management logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and specialized cold chain logistics knowhow. We provide a system that utilizes advanced predictive technology to revolutionize the supply chain by guaranteeing the safety, effectiveness, and potency of every product handled to ensure product integrity, and to provide immediate response in time-sensitive industries while ensuring environmental responsibility.

 

Strategy

 

Our strategy involves leveraging our core competitive strengths to develop and maintain ongoing relationships with a diversified group of customers while continuing to grow our service lines, ensuring that we can meet our customers’ changing needs. We strive to be recognized as the premier provider of logistics and fulfillment of a broad range of value-added services based upon the breadth of those services, quality, responsiveness, customer service, information technologies, safety, and cost effectiveness.

 

We view our solutions as disruptive to the “older technologies” of dry ice and liquid nitrogen, in that our solutions are comprehensive and combine our competencies in configurations that are customized to our client’s requirements. We provide comprehensive, reliable, economic alternatives to all existing logistics solutions and services utilized for frozen shipping in the life sciences industry (e.g., personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). As part of our services, we provide the ability to monitor, record and archive crucial information for each shipment that can be used for scientific and regulatory purposes.

 

30

 

 

Seasonality

 

Based on our industry and our historic trends, we expect our operations to vary seasonally. Typically, revenue will be highest in the third and fourth calendar quarters and lowest in the first and second calendar quarters. These seasonal variations result in fluctuations in waste volumes due to weather conditions and general economic activity. We also expect that our operating expenses may be higher during the winter months due to periodic adverse weather conditions that can slow the collection of waste, resulting in higher labor and operational costs.

 

Results of Operations

 

Three and Nine months ended September 30, 2026, Compared to the Three and Nine months ended September 30, 2025

 

The following table provides certain selected financial information for the periods presented:

 

   (Unaudited)         
   Three months ended Sep 30,         
   2026   2025   Change   Change % 
Revenue  $1,146,699   $1,446,917   $(300,218)   -21%
Cost of Revenue   677,531    953,610    (276,079)   -29%
Gross Profit  $469,168   $493,307   $(24,139)   -5%
Selling, General and administrative expenses   2,669,722    2,372,465    297,257    13%
Total operating expenses  $2,669,722   $2,372,465   $297,257    13%
Income (loss) from operations  $(2,200,554)  $(1,879,158)  $(321,396)   17%
Other income (expense)   (446,632)   (852,183)   405,551    -48%
Income (loss) before income taxes  $(2,647,186)  $(2,731,341)  $84,155    -3%
Provision for income taxes   (3,058)   -    (3,058)   0%
Net income (loss)  $(2,644,128)  $(2,731,341)  $87,213    -3%

 

   (Unaudited)         
   Nine months ended
September 30,
         
   2026   2025   Change   Change % 
Revenue  $3,629,167   $4,562,604   $(933,437)   -20%
Cost of Revenue   2,065,570    2,812,334    (746,764)   -27%
Gross Profit  $1,563,597   $1,750,270   $(186,673)   -11%
Operating Expenses  $-   $-           
Selling, General and administrative expenses   6,902,736    6,274,343    628,393    10%
Total operating expenses  $6,902,736   $6,274,343   $628,393    10%
Income (loss) from operations  $(5,339,139)  $(4,524,073)  $(815,066)   18%
Other income (expense)   (1,840,635)   (847,997)   (992,638)   117%
Income (loss) before income taxes  $(7,179,774)  $(5,372,070)  $(1,807,704)   34%
Provision for income taxes   2,082    1,257    825    66%
Net income (loss)  $(7,181,856)  $(5,373,327)  $(1,808,529)   34%

 

Three Months Ended September 30, 2026 Compared to Three Months Ended September 30, 2025

 

Revenue and Cost of Goods Sold

 

Revenue decreased by $300,218 for the three months ended September 30, 2026, compared to the three months ended September 30, 2025. The decrease was primarily due to a $218,427 decline in product sales and fulfillment services revenue and a $74,465 decline in shipping revenue.

 

Cost of revenue decreased by $276,079 for the three months ended September 30, 2026, compared to the three months ended September 30, 2025, consistent with the lower revenue volume. The decrease was primarily driven by a $198,891 reduction in freight and shipping costs and a $83,325 reduction in direct labor costs associated with fulfillment services.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative (“SG&A”) expenses increased by $297,257 for the three months ended September 30, 2026, compared to the three months ended September 30, 2025. The increase was primarily driven by a $150,000 increase in professional fees, a $89,319 increase in salaries and benefits, a $29,688 increase in public relations and branding expenses and overall increases in travel expenses and legal expenses.

 

31

 

 

Nine Months Ended September 30, 2026 Compared to Nine Months Ended September 30, 2025

 

Revenue and Cost of Goods Sold

 

Revenue decreased by $933,437 for the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025. The decrease was primarily due to a $455,147 decline in government contracts revenue, a $379,366 decline in product sales revenue, and a $119,454 decline in fulfillment revenue, partially offset by a net increase of $20,530 in other revenue.

 

Cost of revenue decreased by $746,764 for the same period, consistent with the decline in revenue. The decrease was primarily driven by a $327,622 reduction in direct labor costs, a $202,326 reduction in transportation costs, a $120,285 reduction in the cost of medical supplies, and a $79,547 reduction in warehouse supplies and equipment.

 

Selling, General and Administrative Expenses

 

Selling, general and administrative (“SG&A”) expenses increased by $628,393 for the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025. The increase was primarily driven by a $150,000 increase in professional fees, increases in salaries and benefits of $236,117, an increase in marketing and advertising of $171,650, and insurance expenses of $52,227.

 

Liquidity and Capital Resources

 

Our principal liquidity requirements are for working capital to fund our operations and growth. To date, we have funded our liquidity requirements through a combination of cash on hand, cash flows from operations, and funding from various sources, including from the CEO. As of September 30, 2026, we had $1,776,719 cash and cash equivalents.

 

As of September 30, 2026, the Company had an accumulated deficit of $(17,441,870) and negative cash flow from operating activities of $(3,999,236) for the nine months ended September 30, 2026. In addition, the Company incurred a net loss of $(7,181,856) for the nine months ended September 30, 2026 and had cash and cash equivalents of $1,776,719 as of September 30, 2026. The Company has recurring losses, has not yet generated sufficient cash flows from operations to fund its activities, and expects to continue incurring operating losses and using cash in support of its business plan.

 

Management’s plans include raising additional capital through sales of common stock under the ELOC Facility and the ATM program, other equity or debt financing, and continued support from our Chief Executive Officer.

 

Under our ELOC Facility with Hexstone Capital, LLC, as amended and restated on August 18, 2026, we may sell up to $75.0 million of our common stock to the investor through April 1, 2027, subject to the conditions of the purchase agreement. During the nine months ended September 30, 2026, we received gross proceeds of $3.0 million from sales under the ELOC Facility. In October 2026, we completed an additional $4.0 million of sales under the ELOC Facility, resulting in net proceeds of $3.66 million after transaction fees. However, the availability and terms of future financing depend on several factors: market conditions, investor demand, the trading price and volume of our common stock, our continued listing on The Nasdaq Capital Market, and our operating performance. There can be no assurance that additional capital will be available when needed or on acceptable terms.

 

In addition, on July 29, 2026, the Company entered into a $1.0 million non-revolving line of credit with First United Bank and Trust Co. to fund working capital. CTS drew the full amount during the third quarter, and no further borrowing availability remains. The Line of Credit is secured by substantially all of CTS’s assets and by collateral pledged by, and unlimited guarantees from related parties. It restricts CTS from incurring additional debt or making distributions without the lender’s consent. As of September 30, 2026, CTS was in compliance with all covenants. The Line of Credit originally matured on October 29, 2026. The lender agreed to extend the maturity by 90 days to January 27, 2027, with all other terms unchanged.

 

In evaluating our ability to meet our obligations as they become due within one year after the date the condensed consolidated financial statements are issued, management considered these conditions, the maturity of the Line of Credit, our cash on hand and our projected operating cash flows. These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date the condensed consolidated financial statements included in this Quarterly Report are issued. Management’s plans have not alleviated that substantial doubt.

 

32

 

 

On April 7, 2026, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders’ equity for continued listing on The Nasdaq Capital Market. The Company submitted a compliance plan to Nasdaq and is working to regain compliance; however, there can be no assurance that the Company will regain compliance within any period granted by Nasdaq.

 

On June 29, 2026, the Company received an additional notice from Nasdaq indicating that it was not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. The Company has until December 28, 2026 to regain compliance with the minimum bid price requirement. The notices have no immediate effect on the listing of the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol “CJMB.”

 

On October 12, 2026, the Company received a determination letter from Nasdaq stating that the Company had not regained compliance with Nasdaq Listing Rule 5550(b), which requires, among other alternatives, a minimum of $2.5 million in stockholders’ equity. The Company subsequently appealed Nasdaq’s determination. On October 15, 2026, Nasdaq acknowledged the Company’s appeal and notified the Company that the delisting action had been stayed pending a final written decision by the Nasdaq Hearings Panel. An oral hearing is scheduled for November 17, 2026.

 

The Company is actively monitoring its compliance with Nasdaq’s continued listing requirements and evaluating alternatives to regain and maintain compliance. There can be no assurance that the Company will regain compliance with the applicable Nasdaq listing standards or otherwise maintain compliance with the continued listing requirements of The Nasdaq Capital Market.

 

   (Unaudited) 
   For Nine months Ended 
   Sep 30, 
   2026   2025   Change 
Cash used in operating activities  $(3,999,236)  $(3,887,737)  $(111,499)
Cash used in investing activities   (35,312)   (616,896)   581,584 
Cash provided by financing activities   3,680,509    5,196,432    (1,515,923)
Increase (decrease) in cash  $(354,039)  $691,799   $(1,045,838)

 

Cash used in operating activities

 

For the nine months ended September 30, 2026, cash used in operating activities was $(3,999,236) compared to $(3,887,737) during the nine months ended September 30, 2025, an increase in cash used of $111,499. The increase was primarily due to the increase in net loss of $1,808,529, partially offset by higher non-cash charges, including $1,368,662 of ELOC-related expenses settled in shares of common stock and $129,499 of common stock issued for professional services, and by a $813,228 favorable change in working capital.

 

Cash used in investing activities

 

For the nine months ended September 30, 2026, cash used in investing activities was $(35,312) compared to $(616,896) for the nine months ended September 30, 2025, a decrease of $581,584. The decrease is a result of the leasehold improvements made to the new corporate office during the nine months ended September 30, 2025, which did not recur in 2026.

 

Cash provided by financing activities

 

During the nine months ended September 30, 2026, cash provided by financing activities was $3,680,509 compared to $5,196,432 during the nine months ended September 30, 2025, a decrease of $1,515,923. The decrease was primarily due to the Company’s initial public offering in 2025, which generated net proceeds of $4,543,988. Financing activities for the nine months ended September 30, 2026 consisted of $2,815,000 of net proceeds from the issuance of shares under the ELOC Facility and $1,000,000 of borrowings under the line of credit, partially offset by $75,000 of deferred offering costs related to the ATM program and $59,491 of advances to an affiliate.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet financing arrangements.

 

33

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Under SEC rules and regulations, because we are considered to be a “smaller reporting company,” we are not required to provide the information required by this item in this report.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our Chief Executive Officer and Chief Financial Officer conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of September 30, 2026, to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, including to ensure that information required to be disclosed by us in the reports filed or submitted by us under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of September 30, 2026, our disclosure controls and procedures were not effective. Management identified a material weakness on the timeliness and consistency of execution of oversight reviews and governance impacting the performance of certain internal control activities, which affected the Company’s ability to consistently achieve its control objectives. During the year ended December 31, 2025, the Company continued to develop and refine its disclosure controls and other procedures designed to ensure that information required to be disclosed in reports filed with the SEC is recorded, processed, summarized, and reported within the time periods specified by SEC rules and forms. In response to the identified ineffectiveness of controls, management has worked on enhancing oversight and governance processes, improving documentation of accounting policies and procedures, and engaged experienced third-party advisors to support GAAP compliance and financial reporting. While progress was made during the year ended December 31, 2025 and has continued through the nine months ended September 30, 2026, remediation of the material weakness will not be considered complete until the redesigned controls have operated effectively for a sustained period and have been validated through testing.

 

(b) Changes in Internal Controls Over Financial Reporting

 

There were no changes in our internal controls over financial reporting that occurred during the last fiscal quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

34

 

 

PART II — OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

During the nine months ended September 30, 2026, the Company finalized a settlement with its former executive related to previously existing claims with no financial impact. There currently is no material pending legal proceeding to which we are a party or to which any of our property is subject, and our management is not aware of any contemplated proceeding by any governmental authority against us. From time to time, we may become involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources, negative publicity, reputational harm, and other factors and there can be no assurances that favorable outcomes will be obtained.

 

ITEM 1A. RISK FACTORS

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this Item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Recent Sale of Unregistered Equity Securities

 

During the three and nine months ended September 30, 2026 no unregistered sales of equity securities occurred.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

35

 

 

ITEM 6. EXHIBITS

 

Exhibit    
Number   Description
3.1   Callan JMB Inc. Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form S-1,as amended (File No. 333-282879), filed with the SEC on January 8, 2025)
3.2   Bylaws, adopted on February 2, 2024 (incorporated by reference to Exhibit 3.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-282879), filed with the SEC on January 8, 2025)
10.1   Form of Equity Purchase Agreement, dated July 24, 2025, by and between Callan JMB Inc. and the Investor (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K (File No. 001-42506) filed with the SEC on July 25, 2025)
10.2   Form of Registration Rights Agreement, dated July 24, 2025, by and between Callan JMB Inc. and the Investor (incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K (File No. 001-42506) filed with the SEC on July 25, 2025)
10.3   Standard Sublease Agreement, dated October 1, 2024, by and between lessor and Callan JMB, Inc.
10.4   Standard Lease Agreement, dated April 1, 2025, by and between Outlaw Run Ranch, LLC. and Coldchain Technology Services, LLC
31.1*   Certification of Co-Chief Executive Officers (Principal Executive Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*   Certification of Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**   Certification of Co-Chief Executive Officers (Principal Executive Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**   Certification of Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

 

* Filed herewith.
** Furnished herewith.

 

36

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  CALLAN JMB INC.
   
  By: /s/ Wayne Williams
    Wayne Williams
    Chief Executive Officer, President, and Chairman of the Board

 

SIGNATURE   TITLE   DATE
         
/s/ Wayne Williams   Chief Executive Officer, President   November 13, 2026
Wayne Williams   (Principal Executive Officer) and Chairman of the Board    
         
/s/ Christopher Shields   Interim Chief Financial Officer   November 13, 2026
Christopher Shields   (Principal Financial and Accounting Officer)    

 

37

Keep reading